Document:

<PAGE>

                                           *** Text Omitted and Filed Separately
                                                Confidential Treatment Requested
                                             Under 17 C.F.R (S)(S) 200.80(b)(4),
                                                            200.83 and 240.24b-2

                                                                   EXHIBIT 10.69

       [LOGO]                               [LOGO]
       INTEGRATED DNA                      SEQUENOM
      TECHNOLOGIES, INC.                       INDUSTRIAL GENOMICS

--------------------------------------------------------------------------------

           High Throughput Oligonucleotide Manufacturing and Supply
             and MassARRAY(TM) Analytical System Purchase Agreement

                                By and between

                                Sequenom, Inc.

             11555 Sorrento Valley Road, San Diego, CA 92121-1331
                    - Hereinafter referred to as Sequenom -

                                      and

                       Integrated DNA Technologies, Inc.

                  1710 Commercial Park, Coralville, IA 52241
                       -Hereinafter referred to as IDT-

                               Table of Contents
<TABLE>
<S>                                                                                 <C>
       Recitals................................................................      2
       Definitions.............................................................      2
       Article 1  Oligonucleotide Supply Period and Deposit....................      6
       Article 2  Synthesizer Assembly and Platform Development Plan...........      6
       Article 3  Assigned Systems Development Plan............................      7
       Article 4  Oligonucleotide Manufacturing and Supply Administration......      9
       Article 5  Pricing, Ordering and Invoicing..............................     10
       Article 6  Intellectual Property........................................     12
       Article 7  Representations & Warranties.................................     14
       Article 8  Qualifications Collaboration.................................     16
       Article 9  Confidential Information.....................................     16
       Article 10 Term and Termination.........................................     18
       Article 11 Notices......................................................     20
       Article 12 General......................................................     21
       Appendix A..............................................................    A-1
       Appendix B..............................................................    B-1
       Appendix C..............................................................    C-1
       Appendix D..............................................................    D-1
</TABLE>

                                                                    CONFIDENTIAL

                                       1
<PAGE>

                                 CONFIDENTIAL

                                   RECITALS

  WHEREAS, Sequenom has developed its MassARRAY(TM) technology platform,
including the MassARRAY(TM) Analytical System, for high definition nucleic acid
and biopolymer analysis; and

  WHEREAS, Sequenom and its customers have a need for large volumes of high
quality oligonucleotides for use with the MassARRAY(TM) technology platform and
Sequenom desires to secure for itself and its customers a dedicated capacity for
oligonucleotide production and a primary and preferred status for the supply of
oligonucleotides; and

  WHEREAS, Sequenom wishes IDT to manufacture oligonucleotides for Sequenom and
to sell oligonucleotides to Sequenom, and in certain instances to deliver
oligonucleotides directly to Sequenom customers; and

  WHEREAS, IDT is a recognized leader in high-volume oligonucleotide synthesis,
and has developed the "High Throughput [...***...] System" a customized,
quality-controlled, high-throughput oligonucleotide synthesis platform; and

  WHEREAS, IDT desires to improve the quality and increase the throughput of its
high-throughput oligonucleotide synthesis platform by combining IDT's High
Throughput [...***...] System with Sequenom's MassARRAY(TM) Analytical System;
and

  WHEREAS, IDT and Sequenom wish to collaborate on the design and production of
oligonucleotides using IDT's High Throughput [...***...] System together with
the MassARRAY(TM) Analytical System;

  NOW THEREFORE, Sequenom and IDT agree to the following:

                                  DEFINITIONS

For purposes of this High Throughput Oligonucleotide Manufacturing and Supply
and MassARRAY(TM) Analytical System Purchase Agreement, the following words,
phrases, or terms shall have the meanings as herein defined:

0.1  "Affiliate shall mean with respect to either Party, a person or entity,
     including without limiting the generality of the foregoing, organizations,
     corporations, partnerships and joint ventures, that directly or indirectly
     through one or more intermediaries, controls, is controlled by or is under
     common control with such person or entity. "Control" (and, with correlative
     meanings, the term "controlled by" and "under common control with") means
     the possession of the power to direct or cause the direction of the
     management and policies of such person or entity, whether through the
     ownership of voting stock, by contract or otherwise. In the case of a
     corporation, "control" shall mean, among other

                                            *** Confidential Treatment Requested

                                       2
<PAGE>

                                 CONFIDENTIAL

      things, the direct or indirect ownership of fifty percent (50%) or more of
      its outstanding voting stock.

0.2   "Agreement" means this High Throughput Oligonucleotide Manufacturing and
      Supply and MassARRAY(TM) Analytical System Purchase Agreement, including
      Appendices A through D, as originally executed and as properly amended
      from time to time according to Article 12.11.

0.3   "Assigned Supply Period" shall mean a period of five (5) years from the
      Assigned Systems Validation Date.

0.4   "Assigned Systems" shall mean [...***...] High Throughput [...***...]
      Systems and the Supporting Equipment to be assigned to and operating
      within, the High Throughput Synthesis Facility Housing to support Sequenom
      and Sequenom Account daily Oligo requirements.

0.5   "Assigned Systems Validation Date" shall mean the date of the signed
      writing contemplated in Article 3.6.2 herein, wherein Sequenom confirms to
      IDT that the Assigned Systems meet or exceed the Validation Criteria.

0.6   "Business Day(s)" shall mean those days from Monday through Friday which
      are not declared as national holidays in the United States, or as holidays
      recognized by either or both Parties.

0.7   "Calendar Days" means all days Sunday through Saturday, which appear on
      the calendar from January 1 through December 31.

0.8   "Customer Deposit" shall mean the credit for dedicated Oligo supply and
      Oligo purchases obtained by Sequenom under this Agreement, which will be
      credited to the benefit of Sequenom against Oligo purchases by Sequenom at
      a rate of [...***...] per base in accordance with terms and conditions of
      Article 5.1.

0.9   "Dedicated Data Management System" means the components of an integrated
      hardware and software system designed to support the isolated processing,
      tracking and storage of all information related to Sequenom and Sequenom
      customer Oligonucleotide orders, with access secured from any party other
      than IDT or Sequenom.

0.10  "Effective Date" shall be the execution date of the last signature on the
      signature page of this Agreement.

                                            *** Confidential Treatment Requested

                                       3
<PAGE>

                                 CONFIDENTIAL

0.11  "High Throughput [...***...] System" or "[...***...] System" shall mean a
      fully integrated bench of DNA synthesizers, chemical/reagent fluidics
      systems, and custom production software, capable of synthesizing (with
      appropriate material inputs and personnel) [...***...] Oligonucleotide
      bases per 24-hour period.

0.12  "High Throughput Synthesis Facility Housing" shall mean the IDT structure
      containing a production area, which is to be dedicated to the manufacture
      of oligonucleotides for large volume customers.

0.13  "IDT" means Integrated DNA Technologies, Inc. and its Affiliates.

0.14  "Intellectual Property" means (i) inventions (whether patentable or
      unpatentable and whether or not reduced to practice), all present
      improvements thereto and future improvements thereto, and all United
      States, and foreign patents, patent applications, patent disclosures, and
      patentable inventions, together with all reissuances, continuations,
      continuations-in-part, divisionals, revisions, extensions and
      reexaminations thereof; (ii) trademarks, trade names, service marks, trade
      dress, logos, and corporate names, together with all translations,
      adaptations, derivations and combinations thereof whether registered or
      arising under the common law, state law or federal law of the United
      States, or the laws of other foreign countries, and all interests therein
      throughout the world and all associated goodwill therewith, and all
      applications, registrations and renewals in connection therewith, all
      copyrights and all copyrightable works and interests throughout the world
      and all other literary property and author rights whether or not
      copyrightable, and all applications, registrations and renewals in
      connection therewith; (iii) mask works and all applications, registrations
      and renewals in connection therewith; (iv) all trade secrets and trade
      secret rights arising under the common law, state law, and federal law of
      the United States, and the laws of other foreign countries, and
      confidential information (including product specifications, data, know-
      how, formulae, compositions, processes, designs, sketches, photographs,
      graphs, drawings, samples, inventions and ideas, past, current research
      and development, current research methodologies and processes, customer
      lists, current and anticipated customer requirements, price lists, market
      studies, business plans), however documented; (v) proprietary computer
      software and programs (including object code and source code) and other
      proprietary rights and copies and tangible embodiments thereof (in
      whatever form or medium); (vi) database technologies, systems, structures
      and architectures (and related processes, formulae, compositions,
      improvements, devices, know-how, inventions, discoveries, concepts, ideas,
      designs, methods and information) and any other related information,
      however, documented; (vii) any and all information concerning the business
      and affairs of Sequenom (which includes historical financial statements,
      financial projections and budgets, historical and projected sales, capital
      spending budgets and plans, the names and backgrounds of key personnel and
      personnel training and techniques and materials), however documented;
      (viii) any and all notes, analysis, compilations, studies, summaries, and
      other material prepared by or for Sequenom containing or based, in whole
      or in part, on any information included in the foregoing, however
      documented; (ix) all industrial designs and any registrations and

                                             ***Confidential Treatment Requested

                                       4
<PAGE>

                                 CONFIDENTIAL

      applications therefore; (x) all databases and data collections and all
      rights therein; and (xi) any similar or equivalent rights to any of the
      foregoing anywhere in the world.

0.15  "Interim Period" shall mean the period of time beginning on the Effective
      Date and ending upon the Assigned Systems Validation Date.

0.16  "LICENSE AND RESTRICTED USE AGREEMENT" refers to Appendix C, governing the
      purchase and use of MassARRAY Products.

0.17  "MassARRAY(TM) SpectroCHIP(TM)" or "SpectroCHIP(TM)" means Sequenom's
      proprietary 384 SpectroCHIP(TM) that, for purposes of this Agreement, is
      to be used solely for MALDI-TOF mass spectrometry quality control in the
      manufacture of oligonucleotides.

0.18  "MassARRAY Analytical System" refers to the Sequenom materials referenced
      in Appendix C.1 to the LICENSE AND RESTRICTED USE AGREEMENT.

0.19  "Oligonucleotide" or "Oligo" means a plurality of nucleotides or
      nucleotide analogs forming a nucleotide chain and conforming to the
      specifications and criteria set forth in Appendix A, for supply and
      delivery to Sequenom and Sequenom Accounts.

0.20  "Parties" shall refer collectively to Sequenom and IDT, each individually
      referred to as a "Party".

0.21  "Person or Persons" shall mean any person, corporation or other entity.

0.22  "Platform Validation Date" shall mean the date upon which Sequenom
      confirms in a signed writing that the objectives of the Synthesizer
      Assembly and Platform Development Plan (Article 2) have been
      satisfactorily completed, as set forth in Article 2.6.

0.23  "Sequenom" means Sequenom, Inc. and its Affiliates.

0.24  "Sequenom Account" shall mean a user of Sequenom's MassARRAY(TM)
      technology or a prospective Sequenom customer with whom Sequenom has
      actively engaged in discussions regarding the supply of oligonucleotides.

0.25  "Supporting Equipment" shall mean the equipment needed for the processing
      of Oligos and Oligo-related components before and after synthesis, the
      analytical equipment, the computer hardware needed for functional
      integration of the systems, the custom order entry software and related
      computer hardware (e.g., the Dedicated Data Management

                                       5
<PAGE>

                                 CONFIDENTIAL

       System), and other related equipment and furnishings supportive of or
       secondary to the actual synthesis of Oligos.

0.26   "Third-Party Customers" shall mean any persons or entities, other than
       Sequenom and IDT, and other than Sequenom Accounts that order products or
       services from IDT.

0.27   "Validation Criteria" shall mean the Oligonucleotide manufacturing
       capacity, performance, quality control, and data criteria for the
       Assigned Systems as established by the Parties according to Article 3
       herein.

                                   ARTICLE 1
                   OLIGONUCLEOTIDE SUPPLY PERIOD AND DEPOSIT

1.1    Supply Period. For the Assigned Supply Period, IDT will utilize the
       Assigned Systems to manufacture and sell Oligos according to the terms
       and conditions as described in this Agreement. This commitment by IDT
       includes the obligations of IDT to individually staff, train, and fully
       compensate, the personnel needed to operate the Assigned Systems for
       Sequenom, and to otherwise fully manage the production of Oligos for
       Sequenom.

1.2    Supply Deposit. In order to allow for accelerated assembly of the
       required synthesizers, the development of a scaleable MALDI-TOF mass
       spectrometry system, and the development of a customized dedicated on-
       line ordering system, all of which will become part of the Assigned
       Systems, Sequenom will advance Installments to IDT according to the
       Installment Schedule described in Appendix B, that will be allocated and
       counted toward Sequenom's Customer Deposit. IDT intends to use the
       Customer Deposit Installments to implement and complete a Synthesizer
       Assembly and Platform Development Plan (as set forth in Article 2) and an
       Assigned Systems Development Plan (as set forth in Article 3).

1.3    Sale of Oligos. IDT will make and sell Oligos to Sequenom in accordance
       with the pricing provisions contained in Article 5. IDT will invoice
       Sequenom at the [...***...] per base, for each base of each Oligo ordered
       by Sequenom and shipped by IDT, and shall reduce Sequenom's Customer
       Deposit by an equivalent sum.

                                   ARTICLE 2
                           SYNTHESIZER ASSEMBLY AND
                           PLATFORM DEVELOPMENT PLAN

2.1   Overview. In order to facilitate the manufacture and supply of Oligos
      under this Agreement, and upon receipt of the Second Installment as set
      forth in Appendix B, IDT will proceed with the following duties and
      obligations which are collectively referred to herein as the "Synthesizer
      Assembly and Platform Development Plan".

                                            *** Confidential Treatment Requested

                                       6
<PAGE>

                                 CONFIDENTIAL

2.2  Synthesizer Assembly. IDT will purchase the required components for,
     assemble and validate the performance of, [...***...] System synthesizers
     in IDT's existing facility in Coralville, Iowa.

2.3  MassARRAY Analytical System Purchase. IDT will purchase a MassARRAY
     Analytical System and SpectroCHIPs (subject to the terms and conditions set
     forth in Appendix C) from Sequenom for integration with the [...***...]
     System synthesizers (referred to in paragraph 2.2) and will establish a
     scaleable platform for high throughput Oligonucleotide analysis.

2.4  Software Development for On-line Ordering. IDT will complete the software
     package for Sequenom's dedicated on-line ordering system and will validate
     its operational performance.

2.5  Interim Capacity Expansion. Pending completion of the Assigned Systems and
     the High Throughput Synthesis Facility Housing, IDT will increase
     oligonucleotide production capacity within its present facility to allow
     for production runs of at least [...***...] Oligos (average length of
     approximately thirty (30) bases) per 24-hour day, solely for Sequenom.

2.6  Confirmation of Completion. IDT will provide written notice to Sequenom of
     its completion of the Synthesizer Assembly and Platform Development Plan,
     upon which Sequenom will have fifteen (15) Business Days to confirm in
     writing, such completion to the reasonable satisfaction of Sequenom. IDT
     agrees that Sequenom representatives will be permitted to observe and
     confirm the satisfactory completion of the duties and obligations of IDT
     described in Article 2. Sequenom agrees to notify IDT in writing of its
     objections, if any, to IDT's performance under this Synthesizer Assembly
     and Platform Development Plan within the fifteen (15) Business Day
     confirmation period. Such written confirmation by Sequenom, or expiration
     of the confirmation period without notice of objections to IDT, will
     establish the "Platform Validation Date". IDT agrees to complete its duties
     and obligations under Article 2 by approximately October 31, 2000.

                                   ARTICLE 3
                       ASSIGNED SYSTEMS DEVELOPMENT PLAN

3.1  Overview. Upon successful completion and validation of the Synthesizer
     Assembly and Platform Development Plan, confirmed in writing by Sequenom,
     ("the Platform Validation Date"), and upon receipt of the Third Installment
     as set forth in Appendix B, IDT will continue, and will accelerate as
     necessary, the performance of the following duties and obligations which
     are collectively referred to herein as the "Assigned Systems Development
     Plan".

3.2  Assigned Capacity Development. IDT will continue its construction of the
     High Throughput Synthesis Facility, with an assigned manufacturing capacity
     dedicated solely

                                            *** Confidential Treatment Requested

                                       7
<PAGE>

                                 CONFIDENTIAL

     to supplying Oligos to Sequenom and Sequenom customers, of [...***...]
     Oligos per day (based upon an average Oligo length of thirty (30) bases).

3.3  Assigned Systems Assembly and Acquisition. IDT will begin the timely
     acquisition of the Supporting Equipment, and will make all manufacturing,
     personnel management and related preparations for the operation of the
     Assigned Systems to begin as soon as commercially practical following the
     completion of the High Throughput Facility Housing.

3.4  MassARRAY Analytical System Purchase. Within five (5) days of the Platform
     Validation Date, IDT will purchase a second MassARRAY Analytical System and
     SpectroCHIPs (subject to the terms and conditions set forth in Appendix C)
     from Sequenom for integration with the [...***...] System Synthesizers
     (referred to in paragraph 2.2) and will establish this secondary system for
     high throughput oligonucleotide analysis as a part of the Assigned Systems,
     and which will be available on a secondary basis for IDT to independently
     supply Third-Party Customers with oligonucleotides.

3.5  Reporting Requirements. IDT will supply Sequenom with written updates of
     progress made on the Assigned Systems Development Plan on the last day of
     each month during the Interim Period. In addition IDT shall immediately
     notify Sequenom in writing of each the following:

     (i)   completion of the High Throughput Synthesis Facility Housing;

     (ii)  completion of the full assembly and integration of the Assigned
           Systems operating within the High Throughput Synthesis Facility
           Housing; and

     (iii) any events, incidents, or occurrences that will materially change, or
           materially affect the timely completion of the High Throughput
           Synthesis Facility Housing or the Assigned Systems Development Plan.

3.6  Validation Criteria. No less than two (2) months following the Platform
     Validation Date, IDT and Sequenom will establish Validation Criteria for
     the Assigned Systems for the daily production of Oligos, that is, in
     addition to the criteria set forth in paragraph 3.2. IDT will assemble and
     integrate the Assigned Systems within the High Throughput Synthesis
     Facility Housing so as to meet or exceed such Validation Criteria.

     3.6.1  Initial Validation by IDT. As soon as is commercially practical
            following the notice described in paragraph 3.5(ii), IDT will
            independently perform an initial trial validation of the Assigned
            Systems within the High Throughput Synthesis Facility Housing, and
            will immediately report to Sequenom in writing the resulting
            validation data in a format consistent with the Validation Criteria.

     3.6.2  Validation & Confirmation by Sequenom. Within twenty (20) days of
            Sequenom's receipt of validation data, which data meets or exceeds
            the

                                            *** Confidential Treatment Requested

                                       8
<PAGE>

                                 CONFIDENTIAL

          Validation Criteria, Sequenom shall have the option, but not the
          obligation, to send at least two (2) representatives to IDT's facility
          in Coralville, for the purpose of confirming that the Assigned Systems
          meet the Validation Criteria agreed to by the Parties.  IDT agrees to
          operate the Assigned Systems in the presence of the representatives of
          Sequenom, and to provide any and all information reasonably necessary
          to confirm compliance of the Assigned Systems with the Validation
          Criteria.  Immediately thereafter the Sequenom representatives shall
          either confirm in writing their validation of the Assigned Systems, or
          shall specify in writing the Validation Criteria (or criterion) that
          have not been met, or for which there is inadequate confirming data.
          IDT shall be given reasonable opportunity to remedy any objections
          raised by the representatives of Sequenom, but in no event more than
          forty-five (45) days to remedy all valid objections.  Immediately
          following successful remedy of Sequenom's objections, Sequenom shall
          confirm in writing, the validation of the Assigned Systems operating
          within the High Throughput Synthesis Facility Housing (the "Assigned
          Systems Validation Date"), and thereafter as set forth in Appendix B,
          pay to IDT the Fourth Installment.

3.7  Completion Dates. IDT will use its best efforts to complete the High
     Throughput Facility Housing by approximately February 28, 2001, and within
     three (3) months after the completion thereof, the Assigned Systems will be
     fully integrated and operational within the High Throughput Facility
     Housing and complete and ready for manufacture of Oligos as set forth in
     Article 5.

                                   ARTICLE 4
                         OLIGONUCLEOTIDE MANUFACTURING
                           AND SUPPLY ADMINISTRATION

4.1  Appointment of Project Managers. It is contemplated by the Parties, that
     all decisions affecting or regarding Oligo specifications, manufacturing,
     and supply, will be the result of informed deliberation and mutual consent
     of designated officials of the Parties. Accordingly, IDT hereby appoints
     William (Trey) Edward Martin III, Vice President of Oligonucleotide
     Manufacturing, and Sequenom hereby appoints Dr. Michael Willis, Ph.D.,
     Senior Director of Chemistry, as the Project Managers for each respective
     Party. The Project Managers, or their duly authorized designates, have the
     authority to make any decision regarding modifications to the
     specifications or criteria requirements (that is, Appendix A) of Oligos,
     but are not authorized to make any decisions regarding pricing, or other
     material issues that conflict with the terms of this Agreement. The Project
     Managers will distribute their joint decisions as they relate to the
     ordering, manufacturing and shipping specifications of Oligos to the
     relevant members of their staffs, and will further instruct all staff
     members to channel all related issues or concerns through Project Managers
     or their designates.

                                       9
<PAGE>

                                 CONFIDENTIAL

4.2  Executive Oversight. The Parties further recognize that the regular review
     and input of senior level executive staff may be beneficial to the Parties
     and accordingly the Parties agree to appoint at least one (1) individual of
     each Party, in addition to the Project Managers, to serve on the Executive
     Committee. The Executive Committee will be formed and will hold its first
     meeting no later than one (1) month from the Effective Date. The Executive
     Committee will be charged with reviewing the performance of the Parties,
     forecasting the Oligonucleotide needs and manufacturing capabilities of the
     respective Parties, and monitoring compliance with the Agreement and
     proactively resolving any conflicts that may arise.

4.3  Specifications. Unless and until later amended by the Project Managers,
     Oligos manufactured by IDT and sold to Sequenom and Sequenom Accounts will
     meet or exceed the following requirements and specifications listed in
     Appendix A attached hereto. Sequenom shall provide IDT with written notice
     subject to Article 11, if Sequenom considers IDT to be failing to
     satisfactorily perform its obligations under this Agreement and/or if
     Sequenom believes the pricing or the terms of this Agreement are no longer
     commercially advantageous or beneficial for Sequenom. In such case,
     Sequenom agrees to provide IDT with a reasonable opportunity to address
     Sequenom's concerns. If IDT is unable to resolve the concerns expressed by
     Sequenom within in a period of time satisfactory to Sequenom, Sequenom
     shall not be restricted in any way by the terms of this Agreement to
     purchase oligonucleotides from another party.

                                   ARTICLE 5
                        PRICING, ORDERING AND INVOICING

5.1  Pricing. Subject to the provisions contained in paragraphs 5.2, 5.3, and
     5.6 hereunder, the per base price for Oligos will be adjusted accordingly
     when Sequenom orders the following volumes of Oligos on a per Business Day
     average, such average to be determined for each calendar month:

      (a) [...***...] per base if Sequenom orders between [...***...] Oligos per
      day;

      (b) [...***...] per base if Sequenom orders between [...***...] Oligos per
      day;

      (c) [...***...] per base for orders of between [...***...] Oligos per day;
      and,

      (d) [...***...] per base for orders of [...***...] Oligos per day.

     IDT will invoice Sequenom at the above [...***...] per base, for each base
     of an Oligo ordered by Sequenom and shipped by IDT, and shall reduce

                                            *** Confidential Treatment Requested

                                       10
<PAGE>

                                 CONFIDENTIAL

     Sequenom's Customer Deposit by an equivalent sum. Sequenom shall not be
     able to exhaust its Customer Deposit at a rate [...***...] per base for
     each Oligo ordered and shipped. Sequenom shall not be precluded from any
     discount it would otherwise be entitled to, due to any delays in shipping
     by IDT.

5.2  External Factors & Price Increases. IDT warrants that it has performed
     adequate manufacturing cost-forecasting to ensure that IDT can supply
     Oligos at the above quoted per base prices in commercially viable fashion.
     However, should unforeseeable events beyond the control of IDT cause the
     manufacturing costs of IDT to increase such that the per base cost of
     manufacture exceeds the then applicable per base price [...***...], then
     IDT shall have the right to increase the per base price to restore a
     [...***...] per base margin. The term "unforeseeable events" as used in
     this paragraph includes, but is not limited to:

      (a) new and substantial regulatory or legal restrictions imposed on the
          manufacture of oligonucleotides or related manufacturing processes;

      (b) substantial changes in the quality (or quality system) requirements of
          Oligos requested by Sequenom;

      (c) substantial increase(s) in the cost of necessary oligonucleotide
          manufacturing amidites, reagents, solvents, or quality control
          components, including specifically, the price of MassARRAY
          SpectroCHIPsTM necessary to perform MALDI-TOF mass spectrometry for
          Oligos;

     Should IDT rely upon "unforeseeable events" beyond the control of IDT as a
     basis for a price increase, IDT shall immediately as is practical disclose
     to Sequenom in writing the cause of the price increase, and IDT's relevant
     manufacturing costs in sufficient detail to allow for confirmation of the
     costs by Sequenom.

5.3  Price Decreases. If there are substantial decreases in the price of the
     necessary amidites/reagents, or changes in the specifications of Oligos
     that result in reduced manufacturing costs of [...***...] average cost per
     base for IDT, and only in those circumstances, then IDT shall reduce the
     per base price to Sequenom by [...***...].

5.4  Oligo Ordering. During the Assigned Supply Period, Sequenom shall place all
     orders for Oligos over the Dedicated Data Management System, using the
     customer order entry software developed by IDT for Sequenom pursuant to
     Article 2.4.

5.5  Oligo Specifications & Manufacturing Turnaround. The specifications and
     requirements for the manufacture of Oligos will be those specifications and
     requirements identified in Appendix A, as amended in writing from time-to-
     time by the Project Managers.

                                            *** Confidential Treatment Requested

                                       11
<PAGE>

                                 CONFIDENTIAL

5.6  Direct Shipment to Sequenom Accounts. IDT will manufacture and directly
     ship Oligos to certain Sequenom customers at the direction of Sequenom. If
     such direct shipment is not specified by Sequenom, IDT will ship Oligos to
     Sequenom. IDT's per base price to Sequenom for direct shipment to Sequenom
     customers will be [...***...] than the price that would have been charged
     to Sequenom under the pricing schedule outlined in Article 5.1 herein. The
     number of Oligos ordered by Sequenom customers, will be included in the
     daily Oligo count averages that determine the corresponding price per base
     to Sequenom as set forth in Article 5.1. Sequenom will independently
     invoice the sale of Oligos directly shipped from IDT to Sequenom customers.

5.7  Supply Forecasts & Pricing. On or before the 20th of each month during the
     Assigned Supply Period, Sequenom will supply IDT with a forecast of its
     intended Oligo orders for the following month (hereinafter "MAO
     Forecasts"). IDT will advise Sequenom within three (3) Business Days of
     receipt of a MAO Forecast of its ability to meet the MAO Forecast. It is
     the expectation of both Parties that IDT will be able to meet any MAO
     Forecast that requires a Business Day daily Oligo average of [...***...]
     Oligos or less.

5.8  Invoicing. During the Assigned Supply Period, IDT will invoice Sequenom
     following the close of each month for Oligos delivered. Payment of the
     invoice by Sequenom will be due within five (5) Business Days from receipt
     of the invoice by Sequenom, and payment will be made by electronic wire
     transfer into an account as designated by IDT. Should Sequenom fail to pay
     the full invoice within thirty (30) Business Days, IDT will have the right
     to suspend Oligo manufacturing until the invoice is paid in full.

5.9  Covenant not to Compete. IDT agrees and covenants that for the duration of
     the Assigned Supply Period, IDT shall not compete with Sequenom for the
     sale of Oligos, meaning that IDT will not knowingly and independently sell
     Oligos to Sequenom Accounts, without the express prior written consent of
     Sequenom. Should Sequenom, in its sole discretion, elect not to supply a
     Sequenom Account with Oligos, Sequenom will authorize IDT to sell Oligos to
     that customer and Sequenom will identify IDT as a possible supplier to that
     customer. However, as long as IDT does not use Sequenom's Oligos for the
     purpose of supplying oligonucleotides to Third-Party Customers, and except
     as specifically described in this paragraph 5.9, nothing in this Agreement
     should be interpreted to prevent IDT from selling oligonucleotides to
     Third-Party Customers.

                                   ARTICLE 6
                             INTELLECTUAL PROPERTY

6.1  Inventions and Discoveries. The Parties do not anticipate, but do
     acknowledge, that Intellectual Property may be developed through the joint
     efforts of the Parties and their employees under this Agreement. If
     Intellectual Property is developed by an individual Party, or by or through
     the joint efforts of the Parties, the ownership of the Intellectual
     Property, whether joint or separate, will be determined by the relevant
     applicable federal

                                            *** Confidential Treatment Requested

                                       12
<PAGE>

                                 CONFIDENTIAL

     or state laws regarding inventorship and reduction-to-practice. In the
     event that an invention or know-how is developed through the joint or
     collaborative efforts of the Parties and their employees, IDT and Sequenom
     agree to instruct their respective employees to report the invention or the
     development in a thorough and prudent manner to the management of the
     respective Parties, and each Party and agrees to notify the other Party of
     the invention or the development as soon as commercially practical
     following internal reporting. The Parties thereafter agree to initiate good
     faith negotiations directed toward the completion of a separate written
     agreement directed to licensing and/or assignment of such Intellectual
     Property.

6.2  Tradenames and Trademarks. IDT acknowledges that MassARRAY(TM),
     SpectroCHIP(TM), SpectroCHECK(TM), and Sequenom(TM), among others, are
     trademarks and tradenames of Sequenom, and that nothing in this Agreement
     is intended as a grant to IDT, express, implied, or otherwise, to use any
     trademark , tradename or trade dress of Sequenom unless expressly agreed to
     in writing by Sequenom. Sequenom, in its sole discretion, may select the
     trademark(s), tradename(s) and trade dress(es), if any, to be used in
     connection with the Oligos, and all such trademarks, tradenames and trade
     dresses are and shall be the exclusive property of Sequenom, and IDT shall
     acquire no interest or right in and to any trademark, trade name or trade
     dress selected or used by Sequenom. IDT agrees not to adopt any trademark,
     trade name or trade dress that may be confusingly similar thereto, and not
     to incorporate, mark, or affix to any Oligo, any IDT trademark.

6.3  Oligonucleotides. Notwithstanding the provisions of Article 6.1 and the
     provisions of Appendix C, Sequenom shall be the sole owner of the Oligos,
     which are the Confidential Information of Sequenom and subject to the
     provisions of Article 9. IDT hereby assigns its entire worldwide right,
     title, and interest, if any, in any Oligo to Sequenom, and IDT agrees to
     take all necessary action to effect any such transfer, and to cooperate
     with and assist Sequenom, at Sequenom's expense, in the pursuit,
     enforcement, and defense of any Intellectual Property rights in any Oligo.
     IDT shall be the sole owner of the Oligonucleotide manufacturing and
     tracking methods developed prior to and/or during the term of this
     Agreement, including, but not limited to, IDT's proprietary: Oligo reagent
     preparation methods, Oligonucleotide synthesis methods, Oligo processing
     and automation protocols, Oligo mass order entry software, Oligo tracking
     software, and Oligo quality control systems.

6.4  Product Labeling. Sequenom will design, purchase and supply IDT with
     product labels and corresponding product packaging to be used with all
     shipments of Oligos. It is understood and agreed to by the Parties that
     Oligos will be labeled as a Sequenom product, and according to labeling and
     packaging requirements and specifications provided by Sequenom.

                                       13
<PAGE>

                                 CONFIDENTIAL

                                   ARTICLE 7
                        REPRESENTATIONS AND WARRANTIES

7.1   Representations and Warranties by IDT:

      IDT represents and warrants as follows:

       (a) IDT is a corporation duly organized, validly existing and in
           corporate good standing under the laws of the state of Iowa;

       (b) IDT has the legal right, authority and power to enter into this
           Agreement;

       (c) IDT has taken all necessary action to authorize the execution,
           delivery and performance of this Agreement;

       (d) upon the execution and delivery of this Agreement, this Agreement
           shall constitute valid and binding obligations against IDT
           enforceable in accordance with its terms, except as enforceability
           may be limited by applicable bankruptcy, insolvency, reorganization,
           moratorium or similar laws affecting creditors' and contracting
           parties' rights generally;

       (e) the performance of its obligations under this Agreement will not
           conflict with its charter documents or result in a breach of any
           agreements, contracts or other arrangements to which it is a Party;

       (f) IDT will not during the term of this Agreement enter into any
           agreements, contracts or other arrangements that would be
           inconsistent with its obligations under this Agreement;

       (g) IDT has obtained, or will obtain, all governmental permits, licenses,
           agreements, contracts, and other enabling documents to fully
           implement and fulfill its duties hereunder;

       (h) IDT represents and warrants that all employees or others acting on
           its behalf pursuant to this Agreement are and shall be obligated
           under a binding written agreement to assign to IDT all inventions
           made or conceived by such employee or other person.

7.2   Representations and Warranties by Sequenom:

      SEQUENOM represents and warrants as follows:

       (a) SEQUENOM is a corporation duly organized, validly existing and in
           corporate good standing under the laws of Delaware;

                                       14
<PAGE>

                                 CONFIDENTIAL

       (b) SEQUENOM has the legal right, authority and power to enter into this
           Agreement;

       (c) SEQUENOM has taken all necessary action to authorize the execution,
           delivery and performance of this Agreement;

       (d) upon the execution and delivery of this Agreement, this Agreement
           shall constitute valid and binding obligations against Sequenom
           enforceable in accordance with its terms, except as enforceability
           may be limited by applicable bankruptcy, insolvency, reorganization,
           moratorium or similar laws affecting creditors' and contracting
           parties' rights generally;

       (e) the performance of its obligations under this Agreement will not
           conflict with its charter documents or result in a breach of any
           agreements, contracts or other arrangements to which it is a Party;

       (f) to the best of SEQUENOM'S knowledge, IDT's manufacture of Oligos does
           not constitute contributory infringement with respect to any issued
           patent of any third party that has issued prior to the effective date
           of this Agreement;

       (g) SEQUENOM will not during the term of this Agreement enter into any
           agreements, contracts or other arrangements that would be
           inconsistent with its obligations under this Agreement;

       (h) SEQUENOM represents and warrants that all employees or others acting
           on its behalf pursuant to this Agreement are and shall be obligated
           under a binding written agreement to assign to SEQUENOM all
           inventions made or conceived by such employee or other person.

7.3  Limited Warranty for Oligos. IDT warrants that Oligos will meet the
     specifications as determined in Appendix A, and as later amended by the
     Project Managers if applicable. This limited warranty represents Sequenom's
     sole and exclusive remedy with respect to Oligos manufactured for and sold
     to Sequenom, or Oligos sold to Sequenom Accounts under this Agreement. IDT
     does not warrant, guarantee or make any representations regarding the use
     or the results of the use of Oligos in Sequenom's MassARRAY Analytical
     System (and MassARRAY assays designed therefor), with respect to
     correctness, accuracy, reliability or otherwise, above and beyond the
     criteria set forth in Appendix A. Sequenom assumes the entire risk as to
     the results obtained from the use of Oligos. Sequenom further acknowledges
     that Sequenom, and not IDT, is solely responsible for any warranty or
     guarantee made to Sequenom Accounts with respect to the performance of
     Oligos. The foregoing warranty is exclusive and is made in lieu of and to
     the exclusion of any other warranties, whether oral or written, express or
     implied, direct or indirect, by estoppel, or by effect of the Uniform
     Commercial Code, usage in the industry or through course of dealings of the
     Parties, including but not limited to those concerning merchantability or
     fitness for a particular purpose.

                                       15
<PAGE>

                                 CONFIDENTIAL

                                   ARTICLE 8
                         QUALIFICATIONS COLLABORATION

8.1  Mutual Interests in Qualification Standards. Sequenom is interested in
     providing its customers with Standard Operating Procedures (hereinafter
     "SOPs") and validation materials that would assist its customers in
     establishing that a laboratory using MassARRAY Products for performing
     high-throughput genotyping services in pharmacogenetic-based clinical
     trials is compliant with United States regulatory standards as set forth in
     the Clinical Laboratory Improvement Amendments of 1988 ("CLIA"), and
     possibly other governmental regulatory standards. IDT is also interested in
     developing SOPs and other validation materials that would establish that
     oligos manufactured by IDT are compliant with United States regulatory
     standards. As a result, the Parties agree as set forth in Articles 8.2 and
     8.3.

8.2  Draft Quality Plan. IDT and Sequenom will collaborate on a draft quality
     plan and supporting quality system for the Assigned Systems, that is
     consistent with (but not necessarily initially compliant with) the relevant
     standards set forth by CLIA. A designated employee or agent of IDT will be
     the principal draftsperson for this initial draft, which will be submitted
     to Sequenom for review by Sequenom, no later than twelve (12) months from
     the Platform Validation Date. A managerial quality control or quality
     assurance employee of Sequenom, will review the initial draft and provide
     written comments to IDT within sixty (60) days of receipt.

8.3  Optional Qualifications Collaboration. Within sixty (60) days of IDT's
     receipt of the review of the initial draft by Sequenom, the Parties agree
     to meet to discuss the potential benefits of further pursuing a
     collaborative effort consistent with this Article 8.

                                   ARTICLE 9
                           CONFIDENTIAL INFORMATION

9.1  Confidential Information. For the purpose of this Agreement, Confidential
     Information means all information, data, and material, labeled or otherwise
     designated or identified as confidential by SEQUENOM or by IDT.

9.2  Designated Confidential Information of Sequenom. All information relating
     to Oligos ordered under this Agreement including but not limited to,
     Oligonucleotide sequences, including specifically, target sequences and/or
     SNPs validated by Sequenom during the course of this Agreement are hereby
     designated as SEQUENOM Confidential Information. SEQUENOM agrees that it
     will, in writing, clearly identify as confidential, any and all additional
     information that it provides to IDT that it considers to be the
     Confidential Information of SEQUENOM.

                                       16
<PAGE>

                                 CONFIDENTIAL

9.3  Designated Confidential Information of IDT. Any and all data generated by
     IDT's development, assembly, validation and use of the High Throughput
     [...***...] Systems and/or the Dedicated Data Management System, except for
     the information described in 9.2 herein, are hereby designated as IDT's
     Confidential Information. IDT agrees that it will, in writing, clearly
     identify as confidential, any and all such information that it provides to
     SEQUENOM that it considers to be the Confidential Information of IDT.

9.4  Use of Confidential Information. Each Party may use the other Party's
     Confidential Information only for the purpose of performing each Party's
     duties and obligations under this Agreement.

9.5  Obligations of Confidentiality. Except as expressly provided herein,
     SEQUENOM and IDT, and their officers, employees, agents, consultants, and
     authorized representatives (a) shall hold in strict confidence all
     Confidential Information from the other Party or any of its officers,
     employees, agents or representatives and (b) shall not distribute, disclose
     or disseminate such Confidential Information to any third party without the
     prior written approval of the other Party (that is, the original disclosing
     Party), provided, however, that such approval will not be unreasonably
     withheld where the receiving Party reasonably believes that disclosure of
     the other Party's Confidential Information is reasonably necessary to
     obtain patents, authorization to conduct clinical trials, or regulatory
     approval.

9.6  Other Information. For purposes of this section, information will not be
     considered to be Confidential Information of a Party if the information:

     (i)   was lawfully in the receiving Party's possession prior to disclosure
           under this Agreement and was not acquired directly or indirectly from
           the disclosing Party; or

     (ii)  was, at the date of disclosure by the disclosing Party, public
           knowledge; or subsequently becomes public knowledge other than
           through the failure of the receiving Party to comply with its
           obligations of confidentiality under the terms of this Agreement; or

     (iii) was or is acquired by the receiving Party from any third party
           lawfully having possession of such information and who is not under
           an obligation of confidentiality to the disclosing Party; or

     (iv)  was or becomes independently known by the receiving Party without
           utilizing information provided by the disclosing Party and wherein
           such independent knowledge is supported in contemporaneously written
           and dated documentation of the receiving Party; or

     (v)   is required to be disclosed, retained, or maintained by either Party,
           by applicable law or regulation or under the rules of any regulatory

                                            *** Confidential Treatment Requested

                                       17
<PAGE>

                                 CONFIDENTIAL

     (vi)  or governmental authority, provided however that each Party shall
           immediately notify the other Party in writing of such required
           disclosure and must provide such notice at least thirty (30) days
           prior to the date when disclosure is proposed to take place, and
           provided that the Party or third party required to make disclosure
           shall use its best efforts to secure confidential treatment of any
           such information required to be disclosed.

9.7  Additional Remedies. The Parties hereto understand and agree that remedies
     at law may be inadequate to protect against any breach of any of the
     provisions of this Article 9 by either Party or their employees, agents,
     officers or directors or any other person acting in concert with it or on
     its behalf. Accordingly, each Party shall be entitled to the granting of
     injunctive relief by a court of competent jurisdiction against any action
     that constitutes any such breach of this Article 9.

9.8  Publications. Either Party may publish or present data and/or results
     generated under this Agreement, provided that, the proposed disclosure
     shall be subject to the prior review by the other Party solely to determine
     (i) whether the proposed disclosure contains the Confidential Information
     of the other Party, (ii) whether the information contained in the proposed
     disclosure should be the subject of a patent application prior to such
     disclosure or (iii) whether the disclosure would be adverse to the business
     interests of the other Party. Each Party shall provide the other Party with
     the opportunity to review any proposed abstract, manuscript or presentation
     by delivering a copy thereof to the other Party no less than thirty (30)
     days before its intended submission for publication or presentation. The
     other Party shall have thirty (30) days from its receipt of any such
     abstract, manuscript or presentation in which to notify the Party in
     writing of any specific objections to the disclosure. In the event a Party
     objects to the disclosure, the other Party agrees not to submit the
     publication or make the presentation containing the objected-to information
     until the Party is given a reasonable additional period of time to seek
     patent protection for any material in the disclosure which it believes is
     patentable or, in the case of Confidential Information, to allow the Party
     to delete any Confidential Information of the other Party from the proposed
     disclosure. Each Party agrees to delete from the proposed disclosure any
     Confidential Information or information that would be adverse to the
     business interests of the other Party upon request.

9.9  Extended Term. The provisions of this Article 9 shall survive any
     termination or expiration of this Agreement and continue in force for a
     period of five (5) years.

                                  ARTICLE 10
                             TERM AND TERMINATION

10.1 Term. The term of this Agreement will be from the Effective Date and will
     continue for a period of five (5) years from the Assigned Systems
     Validation Date, unless terminated by a Party or the Parties under one of
     the provisions of this Article 10.

                                       18
<PAGE>

                                 CONFIDENTIAL

10.2  Bankruptcy. This Agreement shall terminate upon written notice subject to
      Article 11, by one Party to the other Party in the event the other Party
      shall become insolvent, asks its creditors for a moratorium, files a
      bankruptcy petition, or suffers appointment of a temporary or permanent
      receiver, trustee, or custodian, for all or a substantial portion of its
      assets.

10.3  Termination. Either Party may terminate this Agreement for default by the
      other Party in performing any of its material obligations under this
      Agreement by notifying the other Party in writing of such default and
      allowing the other Party thirty (30) days within which to cure such
      default, unless the default is the failure to pay money, in which case the
      defaulting Party shall have only ten (10) Business Days to cure such
      default after receiving written notice of non-payment. If such default is
      not cured within thirty (30) days from receipt of such notice of default
      (or ten (10) Business Days in the case of non-payment of money owed), the
      non-defaulting Party may terminate this Agreement by written notice,
      subject to Article 11, to the defaulting Party.

10.4  IDT Elective Termination. IDT may terminate this Agreement if SEQUENOM has
      failed to order a Business Day daily average of [...***...] or more
      Oligos, calculated over a consecutive ten (10) Business Day period, by the
      second anniversary date (two years from the Effective Date) of this
      Agreement, by providing SEQUENOM thirty (30) days written notice, subject
      to Article 11, of such termination.

10.5  Sequenom Elective Termination. Sequenom may terminate this Agreement by
      providing IDT thirty (30) days written notice if:

      (i)   the Platform Validation Date is not met within nine (9) months of
            the Effective Date; or

      (ii)  the Assigned Systems Validation Date is not met within eighteen (18)
            months of the Effective Date; or

      (iii) IDT materially fails to comply with any of the Oligonucleotide
            manufacturing or supply requirements set forth in Article 3.2 and in
            Appendix A. The Parties recognize and acknowledge that the
            production of Oligos conforming to the specifications and criteria
            set forth in Appendix A is important to Sequenom and is a material
            term of this Agreement, and further that time is of the essence with
            respect to Sequenom and Sequenom customer demand for
            Oligonucleotides. IDT's failure to materially produce and deliver
            Oligos to Sequenom in quantity as set forth in Article 3.2 and in
            conformity with the specifications and criteria set forth in
            Appendix A, is considered a material breach of this Agreement and
            must be cured to the satisfaction of Sequenom within thirty (30)
            Calendar Days of notice of the same to IDT by Sequenom. Failure by
            IDT to cure such a breach within thirty (30) Calendar Days is
            grounds for Sequenom's elective termination of this Agreement.

                                            *** Confidential Treatment Requested

                                       19
<PAGE>

10.6  Effect Of Expiration Or Termination Of Agreement. Within thirty (30) days
      after expiration or termination (the date of termination will be the date
      upon which the thirty (30) day notice period lapses) of this Agreement,
      each Party shall return to the other Party any and all Confidential
      Information (Article 9) provided by the other Party pursuant to this
      Agreement. Sequenom shall have the right to obtain and use all Oligos for
      which Sequenom has paid and that are in IDT's possession, or are scheduled
      to be produced, at the time of termination. Except to the extent expressly
      provided to the contrary, the rights and obligations of the Parties
      pursuant to Articles 9, 10, 11, and 12 shall survive the expiration or
      termination of this Agreement. Any and all rights of IDT to payments
      accrued through expiration or termination as well as obligations of the
      Parties under firm orders for purchase and delivery of Oligos at the time
      of such expiration or termination shall remain in effect. IDT will have no
      obligation to sell and deliver Oligos to Sequenom or Sequenom Accounts
      that have delivery dates more than five (5) Business Days after the date
      of termination, and in the case of termination under sections 10.2 or
      10.3, the terminating Party has discretion in electing whether firm orders
      will remain in effect. Upon expiration or termination of this Agreement,
      any unused Customer Deposit shall be forfeited by Sequenom and will
      default to IDT. Upon termination of this Agreement by Sequenom under
      Article 10.2, 10.3, or 10.5, IDT shall be required to transfer possession,
      and all title, right and interest in and to the MassARRAY Analytical
      Systems (the Pledged Collateral per Appendix D) immediately to Sequenom.

                                   ARTICLE 11
                                    NOTICES

11.1  All notices and requests required or authorized hereunder shall be given
      in writing either by personal delivery; by registered or certified mail,
      return receipt requested; or by confirmed facsimile followed by first
      class mail or express courier service. Such notice shall be deemed to have
      been given upon such date that it is personally delivered; the date three
      (3) days after it is deposited in the mail; or the date the same is
      received by the receiving Party's fax machine, irrespective of the date
      appearing therein.

11.2  If to IDT, the notice as required by 11.1 shall be addressed to the
      address below or to another address designated by IDT as may change from
      time to time:

      Legal Department
      Attn: Urgent
      Integrated DNA Technologies, Inc.
      1710 Commercial Park
      Coralville, Iowa 52241

      (with additional fax):
      Fax: Attn: Legal -URGENT
           (319) 626-8444
       and (847) 470-8223

                                       20
<PAGE>

                                 CONFIDENTIAL

      with a copy to:

      Dr. Joseph A. Walder
      Chief Executive Officer
      Integrated DNA Technologies, Inc.
      1710 Commercial Park
      Coralville, Iowa 52241

11.3  If to Sequenom, the notice as required by 11.1 shall be addressed to the
      address below or to another address designated by Sequenom as may change
      from time to time:

      Sequenom, Inc.
      Corporate Counsel
      11555 Sorrento Valley Road
      San Diego, CA  92121
      Telephone: (858) 350-0345
      Facsimile: (858) 350-0620

      with a copy to:

      Sequenom, Inc.
      Chief Operating Officer
      11555 Sorrento Valley Road
      San Diego, CA  92121
      Telephone: (858) 350-0345
      Facsimile: (858) 350-0344

                                   ARTICLE 12
                                    GENERAL

12.1  Force Majeure. Except with respect to the payment of money, neither Party
      shall be liable for any failure or delay in its performance under this
      Agreement due to causes, including, but not limited to, acts of God, acts
      of civil or military authority, fires, epidemics, floods, earthquakes,
      riots, wars, sabotage, and governmental actions, which are beyond its
      reasonable control; provided that the delayed Party: (i) gives the other
      Party written notice of such cause and (ii) uses its reasonable efforts to
      correct such failure or delay in its performance. The delayed Party's time
      for performance or cure under this section 12.1 shall be extended for a
      period equal to the duration of the cause.

12.2  Relationship Of Parties. The Parties to this Agreement are independent
      contractors. Neither Party nor their respective Affiliates, employees,
      consultants, contractors or agents, are Affiliates, agents, employees,
      joint ventures of the other, nor do they have any authority to bind the
      other by contract or otherwise to any obligation. Neither Party will
      represent anything to the contrary, either expressly, implicitly, by
      appearance or otherwise.

                                       21
<PAGE>

                                 CONFIDENTIAL

12.3  Assignment. The Parties may not assign this Agreement in whole or in part
      without the consent of the other, except if such assignment occurs in
      connection with the sale or transfer of all or substantially all of the
      assets of a Party to which the subject matter of this Agreement pertains.
      Notwithstanding the foregoing, any Party may assign its rights (but not
      its obligations) pursuant to this Agreement in whole or in part to an
      Affiliate of such Party.

12.4  Successors In Interest. Subject to section 12.3, the rights and
      liabilities of the Parties hereto will bind and inure to the benefit of
      their respective successors, executors and administrators, as the case may
      be.

12.5  Applicable Law. This Agreement shall be governed by and construed in
      accordance with the laws of California, U.S.A., notwithstanding its
      conflicts of law rules. Any litigation between the Parties relating to
      this Agreement shall take place in San Diego County, California and the
      Parties consent to the personal jurisdiction of and venue in the state and
      federal courts within San Diego County, California.

12.6  Dispute Resolution. The Parties hereby agree that they will attempt in
      good faith to resolve any controversy or claim arising out of or relating
      to this Agreement promptly by negotiations. If a controversy or claim
      should arise hereunder, the matter shall be referred to an individual
      designated by the Chief Executive Officer (or the equivalent position) of
      IDT and an individual designated by the President (or the equivalent
      position) of SEQUENOM (the "Representatives").

12.7  Severability. If for any reason a court of competent jurisdiction finds
      any provision of this Agreement, or portion thereof, to be unenforceable,
      that provision of the Agreement shall be enforced to the maximum extent
      permissible so as to affect the intent of the Parties, and the remainder
      of this Agreement shall continue in full force and effect.

12.8  No Waiver. Failure by either Party to enforce any term, or condition of
      this Agreement shall not be deemed a waiver of future enforcement of that
      or any other term, provision, or condition. No waiver of a term,
      provision, or condition of this Agreement in any one or more instances,
      whether by context, implication, express, or otherwise, shall be construed
      to be a further or continuing waiver of such term, provision, or
      condition.

12.9  Counterparts. This Agreement may be executed in one or more counterparts,
      each of which will be deemed an original, but all of which will constitute
      but one and the same instrument.

12.10 Facsimile Copies. For purposes of this Agreement, a signed facsimile copy
      shall have the same force and effect as an original signed Agreement.

12.11 Complete Agreement. This Agreement, including all Appendices, constitutes
      the entire agreement between the Parties with respect to the subject
      matter hereof, and supersedes and replaces all prior or contemporaneous
      understandings or agreements, written or oral,

                                       22
<PAGE>

                                 CONFIDENTIAL

      including the first and Second Letters of Intent, regarding such subject
      matter. No amendment to or modification of this Agrement shall be binding
      unless in writing and signed by duly authorized representative of each
      Party.

12.12 Third Party Beneficiaries. Except as specifically set forth herein, no
      third party beneficiary rights are conferred or are intended to be
      conferred by this Agreement.

12.13 Headings. Headings in this Agreement are for convenience only, and shall
      not be used to and shall not affect the meaning or interpretation of this
      Agreement.

12.14 Construction. This Agreement shall not be strictly construed against any
      Party hereto, regardless of which Party, or how much a Party, contributed
      to the drafting of the Agreement.

12.15 Public Announcements. Any announcements or similar publicity with respect
      to the execution of this Agreement shall be agreed upon between Parties in
      advance of such announcement. The Parties understand that this Agreement
      is likely to be of significant interest to investors, analysts and others,
      and that any of the Parties therefore may make such public announcements
      with respect thereto, provided that the disclosing Party has complied with
      the conditions of this section 12.15. The Parties agree that any such
      announcement will not contain confidential business or technical
      information and, if disclosure of confidential business or technical
      information is required by law or regulation, the disclosing Party will
      use its best efforts to minimize such disclosure and obtain confidential
      treatment for any such information which is disclosed to a governmental
      agency or group. Each Party agrees to provide to the other Party a copy of
      any public announcement as soon as reasonably practicable under the
      circumstances prior to its scheduled release. Each Party shall provide the
      other with an advance copy of any release at least ten (10) Business Days
      prior to the scheduled disclosure. Each Party shall have the right to
      expeditiously review and recommend changes to any announcement regarding
      this Agreement or the subject matter of this Agreement. Except as
      otherwise required by law, the Party whose press release has been reviewed
      shall remove any information the reviewing Party reasonably deems to be
      inappropriate for disclosure.

12.16 Conflicts. In the event that a conflict arises between this Agreement and
      any work order, purchase order, billing statement, or invoice, this
      Agreement will govern and the conflicting terms, provisions, and
      conditions of any such other documents shall be deemed nonexistent, and
      shall not be binding upon either Party.

12.17 Indemnification. Sequenom shall at all times during the term of this
      Agreement and thereafter, indemnify, defend and hold IDT harmless against
      all claims and expenses, including legal expenses and reasonable attorneys
      fees, arising out of the death of, or injury to, any person or persons, or
      out of any damage to property, and against any other claim, proceeding,
      demand, expense and liability of any kind whatsoever resulting from the
      use, consumption, sale or advertisement of Oligos arising from any right
      granted to Sequenom or its Affiliates herein. IDT shall at all times
      during the term of this

                                       23
<PAGE>

                                 CONFIDENTIAL

      Agreement and thereafter, indemnify, defend and hold Sequenom harmless
      against all claims and expenses, including legal expenses and reasonable
      attorneys fees, arising out of the death of, or injury to, any person or
      persons, or out of any damage to property, and against any other claim,
      proceeding, demand, expense and liability of any kind whatsoever resulting
      from the construction and development of the High -Throughput Synthesis
      Facility Housing or the Assigned Systems and/or the production and
      manufacture of Oligos, as required under this Agreement. Notwithstanding
      the above, IDT and Sequenom at all times reserves the right to retain
      counsel of their own to defend IDT's or Sequenom's interest. Sequenom
      shall not be liable to IDT, its successors or assignees, or IDT's
      Affiliates, for any loss of profits, loss of business, interruption of
      business, nor for indirect, special or consequential damages of any kind
      under this Agreement. IDT shall not be liable to Sequenom, its successors
      or assignees, Sequenom's Affiliates, or Sequenom Accounts, for any loss of
      profits, loss of business, interruption of business, nor for indirect,
      special or consequential damages of any kind under this Agreement.

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement by their
duly authorized representatives.

Sequenom, Inc.                         Integrated DNA Technologies, Inc.

By:                                    By:

Signature:  /s/ Delbert F. Foit, Jr.    Signature:  /s/ Joseph A. Walder
          --------------------------              ----------------------

Name:  Delbert F. Foit, Jr.             Name:  Joseph A. Walder
     ------------------------------          ---------------------------

Title:  Chief Operating Officer         Title:  President and CEO
      -----------------------------          ---------------------------

Date:  8/24/00                          Date:  8/24/00
     ------------------------------          ---------------------------

                                       24
<PAGE>

                                 CONFIDENTIAL

                                   APPENDIX A

                    OLIGO SPECIFICATIONS AND OTHER CRITERIA

[...***...]

(9)    Ordering Criteria.

          9.1    Ordering format. Unless alter modified by the Project Managers,
                 Sequenom will submit orders for oligos by e-mail with an
                 attached Microsoft Excel(R) Spreadsheet addressed to
                 orders@idtdna.com.

          9.2    Daily ordering "deadline". Sequenom will submit orders to IDT
                 for Oligos as early in a business day as is commercially
                 practical, but in no event later than 5pm Central Time. Orders
                 for oligos received by IDT after 5pm CT will be considered as
                 received the following Business Day.

                                      A-1
                                            *** Confidential Treatment requested
<PAGE>

                                 CONFIDENTIAL

          9.3    Maximum daily/weekly plate request. The Parties recognize that
                 IDT will be expanding its production capacity during the
                 Interim Period (prior to the Platform Validation Date) to
                 accommodate IDT's growth and the growing needs of Sequenom.
                 However, unless and until later modified by the Project
                 Managers, Sequenom agrees to maintain its daily oligo ordering
                 volume at or below [...***...] a day and its weekly oligo
                 ordering volume at or below [...***...] per week.

(10) Shipping Criteria. IDT will ship Sequenom's oligo orders according to the
     following criteria:

          10.1   Oligos will be shipped in sets of three (3) plates, comprising
                 one (1) plate each of the Untagged Primer, the Tagged Primer,
                 and Extend Primers, (hereinafter a "Plate Set").

          10.2   Plate Sets will be shipped frozen on dry ice.

          10.3   IDT will not ship Plate Sets from its facility on Fridays.
                 (i.e., Plate Sets are not to be shipped such that they arrive
                 at Sequenom on a Saturday or Sunday and therefore cannot be
                 immediately received.)

          10.4   IDT's product shipments to Sequenom are FOB.

(11) Remakes.  Should an oligo not meet the specifications listed in this
     Appendix A or as later amended by the Project Managers, such an oligo will
     be remade immediately.  If the MALDI spectra from the second synthesis
     passes the agreed specifications, it will be loaded in its corresponding
     plate.  If the MALDI spectra from the second synthesis again fails to meet
     agreed specifications, but with an identical pattern on the MALDI spectra,
     one oligo will be loaded in its corresponding plate, and the spectra for
     both oligos will be sent to Sequenom for evaluation.  Sequenom will be
     invoiced for both oligos.

                                      A-2   *** Confidential Treatment requested

<PAGE>

                                 CONFIDENTIAL

                                   APPENDIX B

                     CUSTOMER DEPOSIT INSTALLMENT SCHEDULE

     1.   "First Installment". Sequenom previously paid IDT [...***...] on or
          about June 19, 2000, to be counted toward and allocated to Customer
          Deposit.

     2.   "Second Installment". Five (5) days after signing of Agreement,
          Sequenom pays IDT [...***...] to be counted toward and allocated to
          Customer Deposit.

     3.   "Third Installment". Upon completion by IDT of the Accelerated
          Synthesizer Assembly and Validation Plan, Sequenom pays IDT
          [...***...] to be counted toward and allocated to Customer Deposit.

     4.   "Fourth Installment". Upon completion by IDT of the Assigned Systems
          within the High Throughput Facility Housing and validation confirmed
          in writing by Sequenom, Sequenom pays to IDT [...***...] to be counted
          toward and allocated to Customer Deposit. IDT shall thereafter
          [...***...] to the Customer Deposit.

*** Confidential Treatment Requested

                                      B-1
<PAGE>

                                 CONFIDENTIAL

                                  APPENDIX C

                      LICENSE AND RESTRICTED USE AGREEMENT

This LICENSE AND RESTRICTED USE AGREEMENT (the "Agreement") is part of the High
Throughput Oligonucleotide Manufacturing and Supply and MassARRAY(TM) Analytical
System Purchase Agreement and is made by and between Sequenom, Inc., a Delaware
corporation headquartered at 11555 Sorrento Valley Road, San Diego, CA USA
("SEQUENOM"), and Integrated DNA Technologies, Inc., having a principal place of
business at 1710 Commercial Park, Coralville, IA 52241 (hereinafter "IDT"), each
a "party" and together, the "parties."

                                    RECITALS

WHEREAS, SEQUENOM has developed SEQUENOM's proprietary MassARRAY(TM) technology
for high-throughput and reliable biopolymer analysis utilizing mass spectrometry
(hereinafter "MassARRAY") with particular utility for the detection and analysis
of genetic variation in applications such as production and quality control for
Oligonucleotide manufacturing;

WHEREAS, IDT is a high volume Oligonucleotide manufacturer;

WHEREAS, IDT desires to purchase and license certain MassARRAY Products from
SEQUENOM to improve IDT's Oligonucleotide production capacity and quality
control by utilizing SEQUENOM's MassARRAY Products in combination with IDT's
Oligonucleotide production process, to serve SEQUENOM  and SEQUENOM customer
demand for high quality Oligonucleotides, as set forth in the High Throughput
Manufacturing and Supply and MassARRAYTM Analytical System Purchase Agreement,
and for IDT to serve IDT customer demand, and SEQUENOM desires to grant IDT such
a license according to the terms and conditions herein;

NOW, THEREFORE, in consideration of the mutual covenants and promises contained
herein, IDT and SEQUENOM agree as follows:

                            ARTICLE 1.  DEFINITIONS

1.1  "Affiliate" means with respect to either party a person or entity,
     including without limiting the generality of the foregoing, organizations,
     corporations, partnerships and joint ventures, that directly or indirectly
     through one or more intermediaries, controls, is controlled by, or is under
     common control with, such person or entity. "Control" (and, with
     correlative meanings, the term "controlled by" and "under common control
     with") means the possession of the power to direct or cause the direction
     of the management and policies of such person or entity, whether through
     the ownership of voting stock, by contract or otherwise. In the case of a
     corporation, "control" shall mean, among other

                                      C-1
<PAGE>

                                 CONFIDENTIAL

     things, the direct or indirect ownership of fifty percent (50%) or more of
     its outstanding voting stock.

1.2  "Confidential Information" means any information, including, without
     limitation, the terms of this Agreement, technical information,
     specifications, trade secrets, software, source code, and all supporting
     documentation and materials, related to the MassARRAY Products including
     the MassARRAY Products themselves. Confidential Information further means
     all information, data, and material, labeled or otherwise designated or
     identified as Confidential by SEQUENOM or by IDT. All information relating
     to, price, quantity, discount, and delivery schedule for SEQUENOM's
     MassARRAY Products is hereby designated as SEQUENOM Confidential
     Information.

1.3  "Element" shall mean SEQUENOM's SpectroCHIP(TM) technology required for the
     MassARRAY Analytical System to produce a mass spectrum from [...***...]
     located on the SpectroCHIP. By way of example, each SpectroCHIP contains
     three hundred eighty four (384) Positions, [...***...] Elements are used
     and consumed under this definition.

1.4  "Intellectual Property" means (i) inventions (whether patentable or
     unpatentable and whether or not reduced to practice), all present
     improvements thereto and future improvements thereto, and all United
     States, and foreign patents, patent applications, patent disclosures, and
     patentable inventions, together with all reissuances, continuations,
     continuations-in-part, divisionals, revisions, extensions and
     reexaminations thereof; (ii) trademarks, trade names, service marks, trade
     dress, logos, and corporate names, together with all translations,
     adaptations, derivations and combinations thereof whether registered or
     arising under the common law, state law or federal law of the United
     States, or the laws of other foreign countries, and all interests therein
     throughout the world and all associated goodwill therewith, and all
     applications, registrations and renewals in connection therewith, all
     copyrights and all copyrightable works and interests throughout the world
     and all other literary property and author rights whether or not
     copyrightable, and all applications, registrations and renewals in
     connection therewith; (iii) mask works and all applications, registrations
     and renewals in connection therewith; (iv) all trade secrets and trade
     secret rights arising under the common law, state law, and federal law of
     the United States, and the laws of other foreign countries, and
     confidential information (including product specifications, data, know-how,
     formulae, compositions, processes, designs, sketches, photographs, graphs,
     drawings, samples, inventions and ideas, past, current research and
     development, current research methodologies and processes, customer lists,
     current and anticipated customer requirements, price lists, market studies,
     business plans), however documented; (v) proprietary computer software and
     programs (including object code and source code) and other proprietary
     rights and copies and tangible embodiments thereof (in whatever form or
     medium); (vi) database technologies, systems, structures and architectures
     (and related processes, formulae, compositions, improvements, devices,
     know-how, inventions, discoveries, concepts, ideas, designs, methods and
     information) and any other related information, however, documented; (vii)

                                      C-2  *** Confidential Treatment requested
<PAGE>

                                 CONFIDENTIAL

     any and all information concerning the business and affairs of SEQUENOM
     (which includes historical financial statements, financial projections and
     budgets, historical and projected sales, capital spending budgets and
     plans, the names and backgrounds of key personnel and personnel training
     and techniques and materials), however documented; (viii) any and all
     notes, analysis, compilations, studies, summaries, and other material
     prepared by or for SEQUENOM containing or based, in whole or in part, on
     any information included in the foregoing, however documented; (ix) all
     industrial designs and any registrations and applications therefore; (x)
     all databases and data collections and all rights therein; and (xi) any
     similar or equivalent rights to any of the foregoing anywhere in the world.

1.5  "Limited Field of Use" means the use of the MassARRAY Products for MALDI-
     TOF facilitated Oligonucleotide quality control analysis and further means
     [...***...]

1.6  "MassARRAY Analytical System" refers to the SEQUENOM materials referenced
     in Appendix C.1 hereto.

1.7  "MassARRAY SpectroCHIP(TM) Pack" means a package of ten (10) 384-D
     SpectroCHIPs, each SpectroCHIP containing three hundred eighty-four
     Positions.

1.8  "MassARRAY Products" means the MassARRAY Analytical System, MassARRAY
     SpectroCHIP Packs and MassARRAY SpectroCHIPs.

1.9  "Oligonucleotide" means a plurality of nucleotides or nucleotide analogs
     forming a nucleotide chain.

1.10 "Territory" means IDT facilities located worldwide.

                         ARTICLE 2.  MASSARRAY PRODUCT
                              SUPPLY AND ORDERING

2.1  IDT agrees to purchase and license the MassARRAY Analytical System as
     defined in Appendix C.1, and MassARRAY SpectroCHIP Packs to IDT, and
     SEQUENOM agrees to supply and deliver the MassARRAY Analytical System and
     MassARRAY SpectroCHIP Packs to IDT as set forth herein, subject to the
     limited license provisions under Article 5, and subject to the other terms
     and conditions set forth in this Agreement.

2.2  This Agreement contains the exclusive terms and conditions which apply to
     the supply of all MassARRAY Products, notwithstanding any acknowledgment or
     other business forms ("forms" meaning and including IDT order forms)
     transmitted by SEQUENOM or IDT.  All orders for MassARRAY Products must
     reference this Agreement and all SEQUENOM and IDT acknowledgments and
     transmittals will reference this Agreement and the applicable IDT order
     number.

                                      C-3  *** Confidential Treatment requested
<PAGE>

2.3  IDT will use its best efforts to supply SEQUENOM with a forecast of its
     intended orders on a monthly basis.

2.4  This Agreement is not a purchase order.  Purchases of MassARRAY Products
     hereunder shall be made utilizing IDT's purchase order forms issued by IDT.

2.5  All MassARRAY Product ordering and supply will be administered and executed
     by SEQUENOM.

                       ARTICLE 3.  MASSARRAY PURCHASING,
                        LICENSE FEES AND PAYMENT TERMS

3.1  MassARRAY Analytical System.  A one-time purchase price of [...***...] per
     ---------------------------
     MassARRAY Analytical System (which includes a [...***...] license to
     SEQUENOM's proprietary SpectroCHECK(TM) software for the duration of this
     Agreement and subject to return under Article 6.3) will be paid by IDT to
     SEQUENOM. IDT agrees to purchase two (2) MassARRAY Analytical Systems in
     accord with the schedules set forth in Articles 2 (paragraph 2.3) and
     Article 3 (paragraph 3.4) of the High Throughput Oligonucleotide
     Manufacturing and Supply and MassARRAY(TM) Analytical System Purchase
     Agreement. Payment will be made in cash funds and will be due prior to
     shipment.

3.2  MassARRAY SpectroCHIP.  The purchase price of a MassARRAY SpectroCHIP Pack
     ---------------------
     is [...***...] each. This price for the MassARRAY SpectroCHIP Pack is based
     upon a license fee of [...***...] per Element. This price is for a
     MassARRAY SpectroCHIP Pack with each SpectroCHIP Pack containing ten (10)
     384-D SpectroCHIP chips, wherein each chip contains three-hundred eighty
     four (384) Positions. Payments for the MassARRAY SpectroCHIP Packs will be
     made in cash funds and will be due thirty (30) days from the date of
     shipment. All payments under this Agreement will be made to SEQUENOM. Upon
     shipment of MassARRAY SpectroCHIP Packs, SEQUENOM will submit an invoice
     reflecting an invoice number, date, remit to address, order number,
     quantity ordered, unit price, and any applicable tax and shipping and
     handling charges. The configuration of the MassARRAY SpectroCHIP Packs
     and/or MassARRAY SpectroCHIPs may change and/or be improved from time to
     time and may or may not be accompanied by a change in purchase price,
     although the license fees per Element agreed to will not change during the
     duration of this Agreement.

3.3  SpectroCHECK(TM) Software.  Notwithstanding IDT having satisfied its
     -----------------------
     purchase price obligation for the MassARRAY Analytical System, title to
     SEQUENOM's proprietary SpectroCHECK(TM) software remains with SEQUENOM and
     is only included as a licensed component, subject to return to SEQUENOM
     upon expiration or termination of this Agreement as set forth under Article
     6.3. Further, nothing in this Agreement should be construed as a grant,
     title, or transfer of ownership of any Intellectual Property rights to IDT,
     such Intellectual Property rights remain in their entirety, held and owned
     by SEQUENOM.

                                      C-4  ***  Confidential Treatment Requested

<PAGE>

                    ARTICLE 4.  MASSARRAY PRODUCT DELIVERY,
                           SHIPMENT AND RISK OF LOSS

4.1  Delivery of MassARRAY Products is within one (1) month, subject to
     acceptance of the order by SEQUENOM and to product availability.

4.2  SEQUENOM will ship according to SEQUENOM standard commercial practice. All
     shipments will be made by SEQUENOM and shall be FOB SEQUENOM's point of
     manufacture in the United States. Title to and risk of loss for the
     MassARRAY Products shall pass to IDT upon delivery by SEQUENOM to a carrier
     designated by IDT or selected by SEQUENOM if IDT does not designate a
     carrier. Special packing or shipping instructions requested by IDT must be
     agreed to by SEQUENOM in writing, and any charges will be billed to IDT.

                          ARTICLE 5.  LIMITED LICENSE

5.1  By this Agreement, SEQUENOM grants IDT the limited right to use the
     MassARRAY Products, in the Territory, without transfer or sublicense
     rights, solely for the Limited Field of Use. Any use of the MassARRAY
     Products outside this scope is prohibited. IDT shall not use the MassARRAY
     Products for the purposes of detecting or discovering polymorphisms or
     mutations in biopolymers, (hereinafter a "Prohibited Use"). A Prohibited
     Use by IDT shall constitute a material breach of this Agreement. The per
     System purchase price of [...***...], the recurring license fees per
     Element, and the related terms agreed to under Article 3, are based upon
     the parties' mutual understanding of this limited right.

5.2  Conditions to Use of MassARRAY Products: IDT acknowledges that the
     MassARRAY Products and the documentation related thereto contains
     Confidential Information of SEQUENOM and that all Intellectual Property
     rights in or to the MassARRAY Products are solely owned and will remain the
     sole property of SEQUENOM. SEQUENOM's proprietary SpectroCHECK(TM) software
     (a component of the MassARRAY Analytical System) is a trade secret and the
     Confidential Information of SEQUENOM. IDT agrees that any and all use of
     the MassARRAY Products by IDT shall be subject to the following conditions
     and obligations: IDT shall (1) use its best efforts to protect and keep
     confidential any Confidential Information contained in the MassARRAY
     Products or otherwise transferred to IDT pursuant to this License And
     Restricted Use Agreement; (2) only disclose the Confidential Information to
     employees, agents, and consultants who have a need-to-know solely for the
     Limited Field Of Use granted by this Agreement, and who have executed
     appropriate written agreements with IDT sufficient to enable IDT to comply
     with the provisions of this Agreement; and (3) not reverse engineer the
     MassARRAY Products or any component thereof to discover SEQUENOM's
     Confidential Information. IDT further acknowledges the extreme importance
     of the confidentiality of the Confidential Information and agrees in
     addition to: (1) use the

                                      C-5  ***  Confidential Treatment Requested
<PAGE>

     MassARRAY Products only in accordance with the Limited Field of Use granted
     by this Agreement, (2) inform its employees, agents and/or consultants of
     the importance of preserving the confidentiality of the Confidential
     Information, (3) maintain a controlled, secure environment for the storage
     and use of the MassARRAY Products.

5.3  With the exception of the right granted under Article 5.1, no other right
     or license is granted to IDT either directly, indirectly, by implication,
     estoppel, or otherwise by SEQUENOM under this Agreement.

5.4  IDT agrees that each Oligonucleotide which is sold or delivered by IDT (or
     by any of IDT's distributors, agents, or representatives) to any of its
     customers or to Sequenom customers, which has been quality-controlled using
     MassARRAY Products, will be accompanied by a printed or electronic
     specification sheet containing a Sequenom logo and a statement indicating
     in substance that such Oligo has been quality-controlled using
     MassARRAY(TM) technology, such statement and logo use to be in a form and
     content mutually agreed upon by the parties. The parties also agree that
     the Project Managers (per Article 4.1 of the High Throughput
     Oligonucleotide Manufacturing and Supply and MassARRAY(TM) Analytical
     System Purchase Agreement) will work together to make the mass spectra
     information generated using Sequenom's MassARRAY technology easily
     accessible to Sequenom, Sequenom's customers and IDT's customers.

                            ARTICLE 6.  TERMINATION

6.1  This Agreement shall terminate upon termination of the High Throughput
     Oligonucleotide Manufacturing and Supply and MassARRAY(TM) Analytical
     System Purchase Agreement or upon written notice by one party to the other
     party in the event the other party shall become insolvent, asks its
     creditors for a moratorium, files a bankruptcy petition, or suffers
     appointment of a temporary or permanent receiver, trustee, or custodian,
     for all or a substantial portion of its assets.

6.2  Either party may terminate this Agreement for default by the other party in
     performing any of its material obligations under this Agreement by
     notifying the other party in writing of such default and allowing the other
     party thirty (30) days within which to cure such default, unless the
     default is the failure to pay money or to deliver Oligonucleotides, in
     which case the defaulting party shall have only ten (10) days to cure such
     default after receiving written notice of nonpayment or nondelivery. If
     such default is not cured within thirty (30) days from receipt of such
     notice of default (or ten (10) days in the case of non-payment of money
     owed or delivery of oligonucleotides owed), the non-defaulting party may
     terminate this Agreement by written notice to the defaulting party. In
     accordance with the Limited Field of Use of the MassARRAY Products granted
     by this Agreement, if IDT fails to comply with the Limited Field of Use
     restrictions provided in this Agreement, SEQUENOM shall consider it to be a
     breach of a material obligation by IDT and all warranties, express or
     implied, shall be deemed null and void. In the event of a Limited Field of
     Use material breach by IDT, SEQUENOM shall have the option of immediately
     terminating this Agreement.

                                     C-6
<PAGE>

6.3  Articles 3.1, 3.2, 3.3, and 10 shall survive the termination or expiration
     of this Agreement. Any and all rights of SEQUENOM to payments of cash funds
     accrued through termination or expiration shall remain in effect. SEQUENOM
     will have no obligation to continue to license and supply MassARRAY
     Products to IDT following termination or expiration. Upon expiration or
     termination of this Agreement, IDT shall have the right to use all
     MassARRAY SpectroCHIP Packs and all MassARRAY SpectroCHIPs for which IDT
     has paid and that are in IDT's possession at the time of termination or
     expiration. The license granted IDT pursuant to Article 5 shall continue
     until all such MassARRAY SpectroCHIP Packs and SpectroCHIPs, are used, upon
     which the license will then terminate. Within thirty (30) days of the
     expiration or termination of this Agreement, IDT will return any and all
     copies of SEQUENOM's proprietary SpectroCHECK(TM) software (and including
     any version of SEQUENOM's software that has been adapted for integration
     with IDT's databases and/or software) to SEQUENOM. Upon expiration or
     termination of this Agreement, and upon the condition that IDT has
     satisfied its purchase price obligation under Article 3.1, IDT will retain
     possession of the MassARRAY Analytical System, excepting SEQUENOM's
     proprietary SpectroCHECK(TM) software which must be returned to SEQUENOM as
     described above. In the case where such purchase price satisfaction
     condition has been met by IDT, IDT may use the MassARRAY Analytical System
     components (except the SpectroCHECK(TM) software) that it retains
     possession of provided that such manner of use does not utilize trade
     secrets or infringe any patent or other Intellectual Property rights of
     SEQUENOM. Should this Agreement expire or terminate prior to IDT having
     satisfied its purchase price obligation under Article 3.1, the MassARRAY
     Analytical System will be returned to SEQUENOM pursuant to SEQUENOM's
     shipping and handling instructions.

                    ARTICLE 7.  INSTALLATION AND ACCEPTANCE

7.1  Installation of the MassARRAY Analytical System by SEQUENOM at IDT is
     included with purchase under Article 3.1. SEQUENOM shall install the
     MassARRAY Analytical System in accordance with SEQUENOM's standard
     installation practice and SEQUENOM will use commercially reasonable efforts
     to schedule and complete installation in a timely fashion. IDT and SEQUENOM
     will cooperate with each other to coordinate the installation effort.

7.2  Installation shall be complete, and acceptance by IDT shall occur, when the
     MassARRAY Analytical System passes SEQUENOM's standard installation and
     test procedures in effect at the time of installation. In the event the
     MassARRAY Analytical System delivered will not pass SEQUENOM's standard
     installation and test procedures, SEQUENOM will use reasonable commercial
     efforts to make the necessary adjustments and/or to replace the MassARRAY
     Analytical System in whole or in part until the System performs as intended
     and passes such tests.

                                     C-7
<PAGE>

                              ARTICLE 8.  TRAINING

8.1  Included with purchase under Article 3.1, SEQUENOM will train designated
     IDT employees in the installation, use, and routine maintenance of the
     MassARRAY Analytical System and SpectroCHIPs in accord with SEQUENOM's
     standard training program and at a mutually convenient time for the
     parties. IDT may request from time to time, due to employee changes,
     increased use, or otherwise, additional training as the need arises.
     SEQUENOM will provide additional training according to a mutually
     convenient schedule and will invoice IDT at a rate to be determined and
     mutually agreed upon in advance, depending upon the nature and extent of
     the additional training required.

                              ARTICLE 9.  WARRANTY

9.1  SEQUENOM warrants that the MassARRAY Analytical will be free from defects
     in materials and workmanship and will conform to SEQUENOM specifications
     and perform accordingly, from the time of installation and for a period of
     at least one (1) year thereafter, so long as the MassARRAY Analytical
     System remains unchanged and in the original condition supplied by
     SEQUENOM. SEQUENOM warrants that the MassARRAY SpectroCHIPs will be free
     from defects in materials and workmanship and will conform to SEQUENOM
     specifications and perform accordingly, for a period of at least two (2)
     months from the date of shipment, so long as the MassARRAY SpectroCHIPs are
     stored according to specifications, and remain unchanged and in the
     original condition supplied by SEQUENOM. The foregoing warranty does not
     include periodic maintenance or calibration recommended for some MassARRAY
     Products. This warranty does not apply to defects resulting from improper
     or inadequate maintenance or calibration by IDT; defects resulting from
     hardware, software, interfacing, or supplies provided by parties other than
     SEQUENOM; defects resulting from unauthorized modification, maintenance, or
     repair, or improper use or operation outside of SEQUENOM specifications for
     the MassARRAY Products or by personnel not authorized by SEQUENOM; or
     defects resulting from abuse, negligence, accident, loss or damage in
     transit. In addition, this warranty does not apply to damage due to (1)
     environmental conditions at the site of installation; (2) operator failure
     to perform standard operating procedures and routine maintenance as
     prescribed in operator manuals; (3) moving (by other than SEQUENOM
     authorized personnel) the MassARRAY Analytical System from its installed
     location; (4) exposure of the MassARRAY Analytical System to Bio-Safety
     Level 3 or 4 (as defined by the United States Occupational Health and
     Safety Administration) agents; or (5) exposure to radioactivity.

9.2  SEQUENOM's sole obligation and liability for any breach of this warranty
     shall be at SEQUENOM's sole discretion and option: (1) to replace the
     MassARRAY Products, in whole or in part, provided that IDT notifies
     SEQUENOM of the defects, SEQUENOM directs IDT to return the defective
     Products to SEQUENOM and IDT returns the Products as directed, at
     SEQUENOM's expense; or (2) to repair (and recalibrate as

                                     C-8
<PAGE>

     necessitated by repair) the MassARRAY Products in whole or in part; or (3)
     to refund the applicable license fee paid for the defective Products, in
     whole or in part. MassARRAY Products may not be returned to SEQUENOM under
     any circumstances without SEQUENOM's prior authorization. SEQUENOM shall
     not be liable, to any extent whatsoever, for any damages resulting from or
     arising out of the use or performance of the MassARRAY Products provided
     under this Agreement, regardless of foreseeability or the form of the cause
     of action, whether in contract, breach of warranty, tort (including
     negligence, strict liability, or otherwise), and including but not limited
     to damages resulting from loss of data, loss of anticipated profits or
     revenue, or any special, direct, indirect, incidental or consequential
     damages.

9.3  The foregoing warranty is exclusive and is made in lieu of and to the
     exclusion of any other warranties, whether oral or written, express or
     implied, direct, indirect, by estoppel or otherwise, or created by
     commercial code or the usage in the industry or the course of dealings of
     the parties, as to any matter whatsoever, including but not limited to
     those concerning merchantability or fitness for a particular purpose.

                          ARTICLE 10.  CONFIDENTIALITY

10.1 Each party may use the other party's Confidential Information only for the
     purpose of performing under this Agreement. All Confidential Information
     remains the sole property of the disclosing party.

     a)   Except as expressly provided herein, SEQUENOM and IDT, their
          Affiliates, officers, employees, agents, consultants, and authorized
          representatives (a) shall hold in strict confidence all Confidential
          Information from the other party or any of its Affiliates, officers,
          employees, agents or representatives and (b) shall not distribute,
          disclose or disseminate such confidential information to any third
          party without the prior written approval of the other party (that is,
          the original disclosing party).

     b)   For purposes of this section, information will not be considered to be
          Confidential Information if the information:

          (i)  was lawfully in either party's possession prior to disclosure
               under this Agreement and was not acquired directly or indirectly
               from the disclosing party; or

          (ii) was, at the date of disclosure by the disclosing party, public
               knowledge; or subsequently becomes public knowledge other than
               through the failure of the receiving party to comply with its
               obligations of confidentiality under the terms of this Agreement;
               or

                                      C-9
<PAGE>

          (iii)  was or is acquired by the receiving party from any third party
                 lawfully having possession of such information and who is not
                 under an obligation of confidentiality to the disclosing party;
                 or

          (iv)   was or is independently known by the receiving party without
                 utilizing information provided by the disclosing party and
                 wherein such independent knowledge is supported in
                 contemporaneously written and dated documentation of the
                 receiving party; or

          (v)    is required to be disclosed, retained, or maintained by either
                 party, by applicable law or regulation or under the rules of
                 any regulatory or governmental authority, provided however that
                 each party shall immediately notify the other party in writing
                 of such required disclosure and must provide such notice at
                 least thirty (30) days prior to the date when disclosure is
                 proposed to take place, and provided that the party required to
                 make disclosure shall use its best efforts to secure
                 confidential treatment of any such information required to be
                 disclosed.

                          ARTICLE 11.  INDEMNIFICATION

11.1 In the event of an accusation, claim or lawsuit brought by a third party
     for infringement of a patent, copyright, or other proprietary right of a
     third party, based upon IDT's use of the MassARRAY Products in accord with
     the product information, notices, and instructions for use provided
     therewith, SEQUENOM shall, at SEQUENOM's sole option and discretion, do one
     of the following:

     a)  Procure for IDT the right to continue such use; or

     b)  Provide a substitute, non-infringing product which provides
         substantially the same results; or

     c)  Defend the accusation, claim or lawsuit and indemnify IDT for any
         damages which may be awarded; provided that IDT (1) provide prompt
         written notice of the accusation, claim or lawsuit to SEQUENOM; (2)
         authorize and provide SEQUENOM with complete control of the defense of
         the accusation, claim or lawsuit and any and all settlements,
         negotiations, compromises, and discussions thereof; (3) cooperate fully
         with SEQUENOM and provide SEQUENOM with such reasonable assistance, as
         SEQUENOM may request in the defense of such accusation, claim or
         lawsuit; and (4) make no statements or admissions directly or
         indirectly related to the MassARRAY Products or intellectual property
         related to the accusation, claim, or lawsuit, or the merits or lack of
         merit of any accusation, claim, or lawsuit, without the ex-press
         written permission of SEQUENOM. Nothing in this provision shall be
         construed to prevent IDT from participating in

                                      C-10
<PAGE>

         (but not controlling) the defense of any such action, with its counsel
         and at its own expense.

                              ARTICLE 12.  NOTICES

12.1 All notices and requests required or authorized hereunder shall be given in
     writing either by personal delivery; by registered or certified mail,
     return receipt requested; or by confirmed facsimile followed by first class
     mail or express delivery. Such notice shall be deemed to have been given
     upon such date that it is so personally delivered; the date three (3) days
     after it is deposited in the mail; or the date the same is received by the
     receiving party's fax machine, irrespective of the date appearing therein.

    If to IDT:                                    If to Sequenom:

    Legal Department                              Sequenom, Inc.
    Attn: Urgent                                  Corporate Counsel
    Integrated DNA Technologies, Inc.             11555 Sorrento Valley Road
    1710 Commercial Park                          San Diego, CA  92121
    Coralville, Iowa 52241                        Telephone: (858) 350-0345
                                                  Facsimile: (858) 350-0620
    (with additional fax):
    Fax: Attn: Legal -URGENT                      with a copy to:
         (319) 626-8444
    and  (847) 470-8223                           Sequenom, Inc.
                                                  Chief Operating Officer
    with a copy to:                               11555 Sorrento Valley Road
                                                  San Diego, CA  92121
    Dr. Joseph A. Walder                          Telephone: (858) 350-0345
    Chief Executive Officer                       Facsimile: (858) 350-0344
    Integrated DNA Technologies, Inc.
    1710 Commercial Park
    Coralville, Iowa 52241

                              ARTICLE 13.  GENERAL

13.1  Force Majeure

Except with respect to the payment of money, neither party shall be liable for
any failure or delay in its performance under this Agreement due to causes,
including, but not limited to, acts of God, acts of civil or military authority,
fires, epidemics, floods, earthquakes, riots, wars, sabotage, disputes, and
governmental actions, which are beyond its reasonable control; provided that the
delayed party: (i) gives the other party written notice of such cause and (ii)
uses its reasonable efforts to correct such failure or delay in its performance.
The delayed party's time for

                                     C-11
<PAGE>

performance or cure under this Paragraph 13.1 shall be extended for a period
equal to the duration of the cause.

13.2  Relationship of Parties

The parties to this Agreement are independent contractors. Neither party nor
their respective Affiliates, employees, consultants, contractors, or agents, are
Affiliates, agents, employees, or joint ventures of the other. Neither party
will represent anything to the contrary, either expressly, implicitly, by
appearance or otherwise.

13.3  Assignment

The parties may not assign this Agreement in whole or in part without the
written consent of the other, except upon the transfer or sale of all, or
substantially all, of the assets of a Party that pertain to the subject matter
of this Agreement, in which case consent is not required.

13.4  Applicable Law

This Agreement shall be governed by and construed in accordance with the laws of
California, U.S.A., notwithstanding its conflicts of law rules.  Any litigation
between the Parties relating to this Agreement shall take place in San Diego
County, California and the Parties consent to the personal jurisdiction of and
venue in the state and federal courts within San Diego County, California.

13.5  Severability

If for any reason a court of competent jurisdiction finds any provision of this
Agreement, or portion thereof, to be unenforceable, that provision of the
Agreement shall be enforced to the maximum extent permissible so as to effect
the intent of the parties, and the remaining provisions shall continue in full
force and effect.

13.6  No Waiver

Failure by either party to enforce any term, provision, or condition of this
Agreement shall not be deemed a waiver of future enforcement of that or any
other term, provision, or condition.  No waiver of a term, provision, or
condition of this Agreement in any one or more instances, whether by context,
implication, express, or otherwise, shall be construed to be a further or
continuing waiver of such term, provision, or condition.

13.7  Counterparts

This Agreement may be executed in one or more counterparts, each of which will
be deemed an original, but all of which will constitute but one and the same
instrument.

                                      C-12
<PAGE>

13.8   Complete Agreement

This Agreement, including all Appendices, constitutes the entire agreement
between the parties with respect to the subject matter hereof. No amendment to
or modification of this Agreement shall be binding unless in writing and signed
by a duly authorized representative of both parties.

13.9   Third Party Beneficiaries

No third party beneficiary rights are conferred or are intended to be conferred
by this Agreement.

13.10  Headings

Headings in this Agreement are for convenience only, and shall not be used to
and shall not effect the meaning or interpretation of this Agreement.

13.11  Construction

This Agreement shall not be strictly construed against any party hereto,
regardless of which party, or how much a party, contributed to the drafting of
the Agreement.

13.12  Public Announcements

Any announcements or similar publicity with respect to the execution of, or
performance under, this Agreement shall be agreed upon among the parties in
advance of such announcement. All parties understand that this Agreement is
likely to be of significant interest to investors, analysts and others, and that
any of the parties therefore may make such public announcements with respect
thereto. The parties agree that any such announcement will not contain
Confidential Information and, if disclosure of Confidential Information is
required by law or regulation, the disclosing party will use its best efforts to
minimize such disclosure and obtain confidential treatment for any such
information which is disclosed to a governmental agency or group. Each party
agrees to provide to the other party a copy of any public announcement as soon
as reasonably practicable under the circumstances prior to its scheduled
release. Except under extraordinary circumstances, each party shall provide the
other with an advance copy of any press release at least five (5) business days
prior to the scheduled disclosure. Each party shall have the right to
expeditiously review and recommend changes to any announcement regarding this
Agreement or the subject matter of this Agreement. Except as otherwise required
by law, the party whose press release has been reviewed shall remove any
information the reviewing party reasonably deems to be inappropriate for
disclosure.

13.13  Conflicts

In the event that a conflict arises between this Agreement and any order, work
order, billing statement, or invoice related to the MassARRAY Products, this
Agreement will govern and the conflicting terms, provisions, and conditions of
any such other documents shall be deemed nonexistent, and shall not be binding
upon either party.

                                     C-13

<PAGE>

                      ARTICLE 14.  MOST-FAVORED LICENSEE

14.1  Most Favored Licensee

If SEQUENOM hereafter grants to a third-party an equivalent or substantially
similar license as granted to IDT in Article 5 herein, but that includes terms
more favorable to the third-party as compared to the terms of the license to
IDT, SEQUENOM shall immediately notify IDT in writing of the grant of such
license, and IDT shall have the right to become subject to the more favorable
terms, going forward. The Parties thereafter agree to formally amend this
Agreement to reflect the adoption of the more favorable terms.

IN WITNESS WHEREOF, the parties have executed this Agreement by their duly
authorized representatives.

Integrated DNA Technologies, Inc.       SEQUENOM, Inc.

By: /s/ Joseph A. Walder                By: /s/ Delbert F. Foit, Jr.
   ----------------------------            -------------------------------

Print Name: Joseph A. Walder            Print Name: Delbert F. Foit, Jr.
           --------------------                   ------------------------

Title: President and CEO                Title: Chief Operating Officer
      -------------------------               ----------------------------

Date:         8/24/00                   Date:          8/24/00
     --------------------------               ----------------------------

                                     C-14
<PAGE>

                                 APPENDIX C.1

                        MassARRAY(TM) Analytical System

High-speed SpectroSCAN(TM) array mass spectrometer for separation, detection and
characterization of the analyte molecules from a miniaturized array; configured
with:

     .  a 10-chip SCOUT MALDI target
     .  high precision x/y positioning stage (4im/step)
     .  low maintenance N\\2\\ UV laser (10Hz) for sample ionization
     .  gridless pulsed ion extraction
     .  125 cm linear TOF analyzer with gated detector
     .  fuzzy logic feedback control
     .  2 GHz digitizer for high-accuracy data acquisition

SpectroJET(TM) dispenser for nanoliter sample transfer, equipped with:

     .  SPIP Micropump with 800 nl chamber volume
     .  droplet volume range of 0.5-2 nl
     .  CV*2 % dispensing precision of the pump
     .  0.1 mm precision of x/y positioning stage
     .  maximum speed of 41.9 cm/sec
     .  PC, controller software

SpectroCHECK(TM)  Workstation

     .  PC
     .  SpectroCHECK(TM) software (for data management and interpretation)

* denotes less than

                                     C-15
<PAGE>

                                  APPENDIX  D

                               PLEDGE AGREEMENT

          THIS PLEDGE AGREEMENT (this "Agreement"), is made by and between IDT
("Pledgor"), and SEQUENOM, INC., ("Secured Party").

          Pledgor and Secured Party hereby agree as follows:

     SECTION 1   Definitions.
     ---------   -----------

          (a)  All capitalized terms used in this Agreement without definition
shall have the meanings ascribed to them in that certain High Throughput
Oligonucleotide Manufacturing and Supply and MassARRAY(TM) Analytical System
Purchase Agreement, dated and executed of even date herewith, by and between
Pledgor and Secured Party (the "Supply Agreement").

          (b)  As used in this Agreement, the following terms shall have the
following meanings:

          "Documents" means this Agreement, the Supply Agreement, and all other
           ---------
appendices, and schedules delivered to Secured Party under the Supply Agreement
or in connection with the Obligations.

          "Event of Default" has the meaning set forth in Section 6.
           ----------------

          "Lien" means any mortgage, deed of trust, pledge, security interest,
           ----
assignment, deposit arrangement, charge or encumbrance, lien, or other type of
preferential arrangement.

          "Obligations" means the liabilities and obligations of Pledgor to
           -----------
Secured Party, created under, arising out of or in connection with the Supply
Agreement and Documents, and whether due or to become due, absolute or
contingent, liquidated or unliquidated, determined or undetermined.

          "Pledged Collateral" has the meaning set forth in Section 2(a).
           ------------------

          "UCC" means the Uniform Commercial Code as the same may, from time to
           ---
time, be in effect in the State of California; provided, however, in the event
that, by reason of mandatory provisions of law, any or all of the attachment,
perfection or priority of the security interest in any Pledged Collateral is
governed by the Uniform Commercial Code as in effect in a jurisdiction other
than the State of California, the term "UCC" shall mean the Uniform Commercial
Code as in effect in such other jurisdiction for purposes of the provisions
hereof relating to such attachment, perfection or priority and for purposes of
definitions related to such provisions.

                                      D-1
<PAGE>

          (c)  Where applicable and except as otherwise defined herein, terms
used in this Agreement shall have the meanings assigned to them in the UCC.

          (d)  In this Agreement, (i) the meaning of defined terms shall be
equally applicable to both the singular and plural forms of the terms defined;
and (ii) the captions and headings are for convenience of reference only and
shall not affect the construction of this Agreement.

     SECTION 2   Security Interest.
     ---------   -----------------

          (a)  As security for the performance of the Obligations, Pledgor
hereby pledges, assigns, transfers, hypothecates and sets over to Secured Party,
and hereby grants to Secured Party a security interest in, all of Pledgor's
right, title and interest in, to and under the assets described in Schedule 1
hereto (collectively, the "Pledged Collateral").

          (b)  Pledgor shall execute and deliver to Secured Party concurrently
with the execution of this Agreement, and at any time and from time to time
thereafter, all financing statements, assignments, continuation financing
statements, termination statements, and other documents and instruments, in form
reasonably satisfactory to Secured Party, and take all other action, as Secured
Party may reasonably request, to effect a transfer of a perfected first priority
security interest in and pledge of the Pledged Collateral to Secured Party
pursuant to the UCC and to continue perfected, maintain the priority of, or
provide notice of the security interest of Secured Party in the Pledged
Collateral and to accomplish the purposes of this Agreement.

          (c)  Pledgor agrees that this Agreement shall create a continuing
security interest in and pledge of the Pledged Collateral which shall remain in
effect until terminated in accordance with Section 17.

     SECTION 3   Covenants.  So long as any of the Obligations remain
     ---------   ---------
unsatisfied, Pledgor agrees that:

          (a)  Pledgor will, at its own expense, appear in and defend any
action, suit or proceeding which purports to affect its title to, or right or
interest in, the Pledged Collateral or the security interest of Secured Party
therein and the pledge to Secured Party thereof.

          (b)  Pledgor shall give prompt written notice to Secured Party (and in
any event not later than thirty (30) days following any change described below
in this subsection) of:  (i) any change in the location of Pledgor's chief
executive office or principal place of business, (ii) any change in the location
of books and records pertaining to Pledged Collateral; (iii) any change in its
name, (iv) any changes in, additions to or other modifications of its trade
names and trade styles, and (v) any changes in its identity or structure in any
manner which might make any financing statement filed hereunder incorrect or
misleading.

          (c)  Pledgor will not surrender or lose possession of (other than to
Secured Party or, with the prior consent of Secured Party, to a depositary or
financial intermediary), exchange,

                                      D-2
<PAGE>

sell, convey, transfer, assign or otherwise dispose of or transfer the Pledged
Collateral or any right, title or interest therein.

          (d)  Pledgor will not create, incur or permit to exist any Liens upon
or with respect to the Pledged Collateral, other than the security interest of
and pledge to Secured Party created by this Agreement.

          (e)  Pledgor shall maintain and preserve its corporate existence, its
rights to transact business and all other rights, franchises and privileges
necessary or desirable in the normal course of its business and operations and
the ownership of the Pledged Collateral, except in connection with any
transactions expressly permitted by the Supply Agreement.

     SECTION 4   Administration of the Pledged Collateral.
     ---------   ----------------------------------------

          (a)  Upon and after the occurrence of any Event of Default: (i)
Secured Party shall be entitled to receive the Pledged Collateral; (ii) Secured
Party shall have the right following prior written notice to Pledgor to take any
action with respect to the Pledged Collateral and exercise all rights of
conversion, exchange, subscription or any other rights, privileges or options
pertaining to the Pledged Collateral as if Secured Party were the absolute owner
thereof; and (iii) Secured Party shall have the right, for and in the name,
place and stead of Pledgor, to execute endorsements, assignments or other
instruments of conveyance or transfer with respect to all or any of the Pledged
Collateral, to file any claims, take any action or institute, defend, settle or
adjust any actions, suits or proceedings with respect to the Pledged Collateral,
execute any and all such other documents and instruments, and do any and all
such acts and things, as Secured Party may deem necessary or desirable to
protect, collect, realize upon and preserve the Pledged Collateral, to enforce
Secured Party's rights with respect to the Pledged Collateral and to accomplish
the purposes of this Agreement.

          (b)  For the purpose of enabling Secured Party to exercise its rights
under this Section 4 or otherwise in connection with this Agreement, Pledgor
hereby (i) constitutes and appoints Secured Party (and any of Secured Party's
officers, employees or agents designated by Secured Party) its true and lawful
attorney-in-fact, with full power and authority to execute any notice,
assignment, endorsement or other instrument or document, and to do any and all
acts and things for and on behalf of Pledgor, which Secured Party may deem
necessary or desirable to protect, collect, realize upon and preserve the
Pledged Collateral, to enforce Secured Party's rights with respect to the
Pledged Collateral and to accomplish the purposes hereof.  This appointment is
coupled with an irrevocable interest so long as the Obligations have not been
performed in full.  Pledgor hereby ratifies, to the extent permitted by law, all
that Secured Party shall lawfully and in good faith do or cause to be done by
virtue of and in compliance with this Section 4.

     SECTION 5   Secured Party's Duties.  Notwithstanding any provision
     ---------   ----------------------
contained in this Agreement, Secured Party shall have no duty to exercise any of
the rights, privileges or powers afforded to it and shall not be responsible to
Pledgor or any other person for any failure to do so or delay in doing so.

                                      D-3
<PAGE>

     SECTION 6   Events of Default.  Any of the following events which shall
     ---------   -----------------
occur and be continuing shall constitute an "Event of Default":

          (a)  The failure of Pledgor to perform its material Obligations under
the Supply Agreement, time being of the essence of all Obligations of Pledgor to
Secured Party;

          (b)  Pledgor makes a general assignment for the benefit of creditors,
generally fails to pay its debts as they come due, or becomes insolvent;

          (c)  Pledgor or any of its subsidiaries shall become a debtor in a
case under Chapter 11 of the United States Bankruptcy Code, or shall otherwise
become the subject of any case, proceeding or process designed for the
protection of debtors or borrowers.

          (d)  Pledgor shall voluntarily or involuntarily transfer or assign any
interest in the Pledged Collateral to any person or entity, including (without
limitation) by granting a security interest therein, or by suffering to exist
any judgment lien thereon;

          (e)  Any impairment in the priority of Secured Party's Lien hereunder
shall occur; or

          (f)  Any levy upon, seizure or attachment of any of the Pledged
Collateral shall be threatened or shall occur.

     SECTION 7  Remedies.
     ---------  --------

          (a)  Upon the occurrence and during the continuance of any Event of
Default, Secured Party may declare any of the Obligations to be immediately due
and shall have, in addition to all other rights and remedies granted to it in
this Agreement or the Supply Agreement, all rights and remedies of a secured
party under the UCC and other applicable laws.

     SECTION 8  Certain Waivers.  Pledgor waives, to the fullest extent
     ---------  ---------------
permitted by law, (i) any right of redemption with respect to the Pledged
Collateral; and (ii) any right to require Secured Party (A) to proceed against
any person, (B) to exhaust any other collateral or security for any of the
Obligations, (C) to pursue any remedy in Secured Party's power, or (D) to make
or give any presentments, demands for performance, notices of nonperformance,
protests, notices of protests or notices of dishonor in connection with any of
the Pledged Collateral; and (iii) all claims, damages, and demands against
Secured Party arising out of the repossession, retention, or other disposition
of the Pledged Collateral by Secured Party.

     SECTION 9  Notices.  All notices or other communications hereunder shall be
     ---------  -------
in writing (including by facsimile transmission) and mailed, sent or delivered
to the respective parties hereto at or to their respective addresses or
facsimile numbers specified for notices under the Supply Agreement, or at or to
such other address or facsimile number as shall be designated by any party in a
written notice to the other parties hereto.  All such notices and other
communications shall be effective (i) if delivered by hand, when delivered; (ii)
if sent by mail, upon the earlier of the date of receipt or five business days
after deposit in the mail, first class (or

                                      D-4
<PAGE>

air mail, with respect to communications to be sent to or from the United
States); and (iii) if sent by facsimile transmission, when sent.

     SECTION 10   No Waiver; Cumulative Remedies.  No failure on the part of
     ----------   ------------------------------
Secured Party to exercise, and no delay in exercising, any right, remedy, power
or privilege hereunder shall operate as a waiver thereof, nor shall any single
or partial exercise of any such right, remedy, power or privilege preclude any
other or further exercise thereof or the exercise of any other right, remedy,
power or privilege.  The rights and remedies under this Agreement are cumulative
and not exclusive of any rights, remedies, powers and privileges that may
otherwise be available to Secured Party.

     SECTION 11   Costs and Expenses.  Pledgor agrees to pay on demand all costs
     ----------   ------------------
and expenses of Secured Party, including the reasonable fees and disbursements
of counsel to Secured Party, in connection with the enforcement or attempted
enforcement of, and preservation of any rights or interests under this
Agreement, including in any out-of-court workout or other refinancing or
restructuring or in any bankruptcy case, and the protection, sale or collection
of, or other realization upon, any of the Pledged Collateral.

     SECTION 12   Binding Effect.  This Agreement shall be binding upon, inure
     ----------   ----------------
to the benefit of and be enforceable by Pledgor, Secured Party and their
respective successors and assigns.

     SECTION 13   Governing Law.  This Agreement shall be governed by, and
     ----------   -------------
construed in accordance with, the law of the State of California.

     SECTION 14   Entire Agreement.  This Agreement (and all exhibits and
     ----------   ----------------
schedules attached hereto), the Supply Agreement (and all representations and
warranties contained therein and appendices and exhibits attached thereto), and
all other documents delivered in connection herewith supercede all prior
discussions and agreements among the parties with respect to the subject matter
hereof and thereof and contains the sole and entire agreement among the parties
hereto with respect thereto.

     SECTION 15   Severability.  Whenever possible, each provision of this
     ----------   ------------
Agreement shall be interpreted in such manner as to be effective and valid under
all applicable laws and regulations.  If, however, any provision of this
Agreement shall be prohibited by or invalid under any such law or regulation in
any jurisdiction, it shall, as to such jurisdiction, be deemed modified to
conform to the minimum requirements of such law or regulation, or, if for any
reason it is not deemed so modified, it shall be ineffective and invalid only to
the extent of such prohibition or invalidity without affecting the remaining
provisions of this Agreement, or the validity or effectiveness of such provision
in any other jurisdiction.

     SECTION 16   Counterparts.  This Agreement may be executed in any number of
     ----------   ------------
counterparts and by different parties hereto in separate counterparts, each of
which when so executed shall be deemed to be an original and all of which taken
together shall constitute but one and the same agreement.

                                      D-5
<PAGE>

     SECTION 17   Termination.  Upon performance in full of all Obligations,
     ----------   -----------
this Agreement shall terminate and Secured Party shall promptly execute and
deliver to Pledgor such documents and instruments reasonably requested by
Pledgor as shall be necessary to evidence termination of all security interests
given by Pledgor to Secured Party hereunder.

     SECTION 18   Conflicts.  In the event of any conflict or inconsistency
     ----------   ---------
between this Agreement and the Supply Agreement, the terms of this Agreement
shall control.

     IN WITNESS WHEREOF, the parties hereto have duly executed this Pledge
Agreement, as of the date first above written.

Sequenom, Inc.                             Integrated DNA Technologies, Inc

By:                                        By:

Signature: /s/ Delbert F. Foit, Jr.        Signature: /s/ Joseph A. Walder
          ---------------------------                -------------------------

Name:      Delbert F. Foit, Jr             Name:       Joseph A. Walder
     --------------------------------           ------------------------------

Title:     Chief Operating Officer         Title:      President and CEO
      -------------------------------            -----------------------------

Date:      8/24/00                         Date:       8/24/00
      -------------------------------           ------------------------------

                                      D-6
<PAGE>

                                   SCHEDULE 1
                            to the Pledge Agreement

                               PLEDGED COLLATERAL

"Pledged Collateral" means the following assets, in each case whether presently
existing or owned or hereafter arising or acquired and wherever located:

     (a)   a first MassARRAY(TM) Analytical System as referred to under Article
2.3 and Appendix C of the Supply Agreement;

     (b)   a second MassARRAY(TM) Analytical System as referred to under Article
3.4 and Appendix C of the Supply Agreement;

                                      S-1<PAGE>

                                                                   Exhibit 10.70

                                            ***Text Omitted and Filed Separately
                                                Confidential Treatment Requested
                                           Under 17 C.F.R.  (S)(S) 200.80(b)(4),
                                                            200.83 and 240.24b-2

                             TECHNOLOGY ACCESS AND
                            COLLABORATION AGREEMENT

                                    between

                                Sequenom, Inc.

                                      and

                             Incyte Genomics, Inc.
<PAGE>

                 TECHNOLOGY ACCESS AND COLLABORATION AGREEMENT

This Technology Access and Collaboration Agreement (the "Agreement"), to be
effective as of the 29th day of September, 2000 (the "Effective Date"), is by
and between Sequenom, Inc. ("Sequenom"), a Delaware corporation having its
principal place of business at 11555 Sorrento Valley Road, San Diego, California
92121, and Incyte Genomics, Inc., a Delaware corporation having a principal
place of business at 3160 Porter Drive, Palo Alto, California 94304, ("Incyte").

                                  BACKGROUND

     WHEREAS, Incyte and Sequenom are interested in conducting certain
scientific research primarily related to the confirmation of Incyte's isSNP
Dataset (as defined below) of single nucleotide polymorphisms ("SNPs") and their
frequency across an ethnic diversity panel and association with morbidity in
accordance with the Project (as defined below);

     WHEREAS Sequenom owns or has access to proprietary MassArray(TM) and
pooling technologies that are useful for making, using and selling genotyping
and SNP assays;

     WHEREAS, Sequenom is willing to provide Incyte with access to those
technologies and to DNA sample pools stratified by age, gender and ethnicity
through Sequenom's use of those technologies and samples in the Project, subject
to the terms and conditions of this Agreement;

     WHEREAS, Incyte owns or has access to the isSNP Dataset consisting of in
silico SNPs located in genes or in gene associated regions; and

     WHEREAS, Incyte is willing to provide information from the isSNP Dataset
and rights to make and sell assays based on such information to Sequenom,
subject to the terms and conditions of this Agreement.

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
and conditions herein recited, the Parties do hereby agree as follows:

1    DEFINITIONS

When used herein the following terms shall have the indicated meanings.

1.1  "Affiliate": shall mean any corporation or business entity that is
      ---------
controlled by, controls, or is under common control of Incyte or Sequenom, as
applicable, at the time of execution of this Agreement.  For this purpose, the
meaning of the word "control" shall mean direct or indirect ownership of one
hundred percent (100%) of the voting shares of such corporation or one hundred
percent (100%) of the ownership interests in such other business entity.

1.2  "Assay": shall mean a procedure and components (including, without
      -----
limitation, primer sets and interpretation software) used by Sequenom or End
Users of Sequenom's mass spectroscopy based technology to test for the presence
or absence of a Project SNP for

                                      1.
<PAGE>

     internal research purposes [...***...] (except for uses by Incyte as
     contemplated by Section 3.2, but not for purposes of generating database
     products).

1.3  "Collaboration IP": shall mean (a) all rights, including all Patent Rights,
      ----------------
     copyrights, trade secret rights and any other intellectual property rights,
     to [...***...]. Notwithstanding anything to the contrary herein, Incyte
     retains the right to utilize the isSNP Dataset for any purpose whatsoever;
     including, without limitation to [...***...]. Nothing in this Agreement
     grants Sequenom any rights to any Incyte technology generated outside the
     course of performing work under the Project. (b) all Patent Rights claiming
     [...***...], where the utility of any such SNP is based [...***...],
     discovered by either Party or by the Parties jointly in the course of
     performing work under the Project, and (c) all rights, including all Patent
     Rights, copyrights, trade secret rights and any other intellectual property
     rights, in [...***...] that is not publicly available without restriction
     on use or disclosure.

1.4  "Collaborator": shall mean a third-party collaborator that enters into a
      ------------
     collaborative program under which Project SNPs are studied with one or both
     of the Parties.

1.5  "Confidential Information" shall mean all technical and business
      ------------------------
     information belonging to a Party, disclosed by one Party to the other
     Party, including, where appropriate and without limitation, any
     information, business information, financial information, data (including
     transcript and nucleic acid sequence data), patent disclosures, patent
     applications, structures, models, designs, drawings, techniques, processes,
     software and hardware configurations, compositions, compounds, apparatus,
     research, development or commercialization plans, trade secrets and the
     like. Confidential Information specifically excludes information of a Party
     which:

     (a)  the receiving Party can demonstrate by written record, either in print
          or electronic media, had been previously discovered by or was known to
          the receiving Party prior to the time of receipt; or
     (b)  was in the public domain at the time of receipt by the receiving
          Party; or
     (c)  becomes part of the public domain through no fault of the receiving
          Party; or
     (d)  is lawfully received by the receiving Party from a third party having
          a right to disclose it to the receiving Party; or
     (e)  is independently developed by the Receiving Party without the aid,
          application, or use of information disclosed hereunder, as can be
          demonstrated by written records, either in print or electronic media,
          created at the time of such independent development.

     The Project Results and Collaboration IP will be considered Confidential
     Information of both Parties.

     The isSNP Dataset will be considered Confidential Information of Incyte,
     and the MassArray Technology and Pooling Technology will be considered
     Confidential Information of Sequenom.

                                      2.     ***Confidential Treatment Requested
<PAGE>

1.6  "Confirmation Data": shall mean information confirming or negating the
      -----------------
     existence in humans of SNPs in the isSNP Dataset, generated by Sequenom in
     the course of its work on the Project, and Confirmation Data includes the
     specific knowledge of each particular SNP in the isSNP Dataset that has
     been confirmed to exist in humans during and under the Project.

1.7  "Contribution Margin": shall mean, with respect to a Party's sales of a
      -------------------
     product subject to the provisions of Article 6 of this Agreement, Revenue
     on such product less Cost of Goods Sold and Sales and Marketing Expenses
     with respect to such product.

1.8  "Cost of Goods Sold": shall mean the cost of a product, including
      ------------------
     Assays (including kits or services performed by Sequenom) and Incyte
     information products, which is equal to the actual unit costs, consisting
     of direct material and direct labor costs plus overhead directly
     attributable to the products at standard, all calculated in accordance with
     generally accepted accounting principles, consistently applied, of the
     applicable Party. Direct material costs shall include the costs incurred in
     purchasing materials, including sales and excise taxes imposed thereon and
     customs duty and charges levied by government authorities, and all costs of
     packaging components. Direct labor shall include the cost of employees
     engaged in direct manufacturing activities and direct and indirect quality
     control and quality assurance activities who are directly employed in
     product manufacturing and packaging. Overhead attributable to the products
     shall include a reasonable allocation of indirect labor (not previously
     included in direct labor), a reasonable allocation of administrative costs,
     and a reasonable allocation of facilities costs.

1.9  "Disease Association Data": shall mean information regarding [...***...]
      ------------------------
     disease or disease control.

1.10 "End User": shall mean any person or entity that purchases an Assay for
      --------
     its own internal research use only.

1.11 "Frequency Data": shall mean information regarding the allele frequency
      --------------
     [...***...], broken down by ethnic category [...***...].

1.12 "Incyte Database": shall mean the version(s) of Incyte's proprietary
      ---------------
     LifeSeq(R) Gold Database (or its equivalent or successor product(s)), as
     provided by Incyte on a non exclusive basis to customers who have
     subscription agreements with Incyte under which Incyte agrees to provide
     them with updated versions of the LifeSeq(R) Gold database.

1.13 "Incyte Patent Rights": shall mean Patent Rights owned by or controlled
      --------------------
     by Incyte, only to the extent however, that Incyte has the right to grant
     licenses thereunder, and only to the extent that they claim: (a) the
     [...***...]; or (b) the [...***...].

                                      3.     ***Confidential Treatment Requested
<PAGE>

1.14  "Incyte Technology": shall mean (i) all or any portion of the isSNP
       -----------------
      Dataset that constitutes Confidential Information of Incyte, and (ii)
      Incyte Patent Rights.

1.15  "isSNP Sequence Data":  shall mean human nucleotide sequence of
       -------------------
      specific in silico SNP(s), and related DNA sequence information derived by
      Incyte using internal and other data sources and Incyte proprietary
      algorithms.

1.16  "isSNP Dataset":  shall mean the collection of isSNP Sequence Data
       -------------
      which shall be provided to Sequenom hereunder.

1.17  "MassArray Technology" shall mean Sequenom's proprietary MassArray(TM)
       --------------------
      mass spectrometry-based technology for high throughput DNA analysis used
      by Sequenom to discover, detect and/or validate SNPs and/or measure their
      allele frequencies.

1.18  "Morbidity Data": shall mean the information [...***...].
       --------------

1.19  "Outside Program": shall have the meaning given such term in Section
       ---------------
      4.3(c).

1.20  "Party": shall mean Sequenom or Incyte and, when used in the plural,
       -----
      shall mean Sequenom and Incyte.

1.21  "Partnership Program": shall mean a collaborative program among Incyte,
       -------------------
      Sequenom and a Collaborator under which Project SNPs are studied or under
      which Collaboration IP is utilized, and which has been mutually agreed
      upon by the Parties.

1.22  "Patent Rights": shall mean all rights under all patents and pending
       -------------
      patent applications, and all patents issuing therefrom (including utility,
      model and design patents and certificates of invention), throughout the
      world and all substitutions, extensions, supplemental protection
      certificates, registrations, confirmations, reissues, renewals,
      reexaminations, divisionals, provisionals, continuations or continuations-
      in-part thereof.

1.23  "Pooling Technology": shall mean Sequenom's proprietary methodology for
       ------------------
      pooling DNA samples for purposes of measuring the allele frequency of SNPs
      in a multiplicity of samples.

1.24  "Primer Sets": shall mean sets of primers (including DNA sequence
       -----------
      information and aliquots of physical primers) for development,
      manufacturing and sale of Assays.

1.25  "Project": shall mean the research project as described in Exhibit A
       -------
      and any modifications thereof or additions thereto as agreed between the
      Parties in writing.

                                      4.     ***Confidential Treatment Requested
<PAGE>

1.26   "Project SNPs": shall mean SNPs from the isSNP Dataset which have been
        ------------
       confirmed in the Project to be human SNPs based on Confirmation Data.

1.27   "Project Results": shall mean jointly and severally, the Confirmation
        ---------------
       Data, the Frequency Data and the Morbidity Data.

1.28   "Revenue": shall mean the gross amounts invoiced or due to be received
        -------
       by a Party or its Affiliates for the sale of an applicable product, less:
       (a) trade, cash and quantity credits, discounts, refunds or rebates or
       retroactive price reductions; (b) commissions paid or allowed to
       distributors who are independent third parties; (c) allowances or credits
       for returns or rejected product; (d) taxes (other than income taxes or
       franchise taxes on the income of the selling Party or its Affiliates)
       actually paid or withheld; and (e) transportation and delivery charges,
       including insurance premiums, actually incurred. In the event a product
       subject to the provisions of Article 6 is sold in combination with one or
       more products which are not subject to the provisions of Article 6,
       Revenue will be calculated by multiplying the sales price of such
       combination product by the fraction A/(A+B) where A is the fair market
       value of the product subject to the provisions of Article 6 and B is the
       total fair market value of the other product(s).

       For purposes of this Agreement, Revenue will include (i) payments that a
       Party receives from a Collaborator pursuant to a Partnership Program or
       an Outside Program and (ii) payments that a Party receives from a third
       party for the grant of a license under any Collaboration IP, in each case
       including royalties, milestone payments, license or technology access
       fees and the premium portion of any equity payment made by the third
       party to a Party in exchange for such Party's shares, and the total
       market value of any shares of any third party entity made as a payment to
       a party, (or the relevant portion of such shares), but excluding cost of
       research or other services actually performed by such Party and the
       portion of any equity payment equal to the fair market value of the
       equity issued. Any in-kind payment received by a Party that would be
       included in Revenue will be valued at the average selling price of the
       applicable product or service sold or provided by such Party. Revenue
       shall not include subscription and/or access fees to Incyte Databases
       except as specifically under 6.6 (b).

1.29   "Sales and Marketing Expenses": shall mean the costs incurred by a
        ----------------------------
       Party or for its account attributable to the distribution, sale,
       promotion and marketing of a product that is subject to the provisions of
       Article 6, plus overhead directly attributable to such activities at
       standard, all calculated in accordance with reasonable cost accounting
       methods, consistently applied, of the applicable Party. Sales and
       Marketing Expenses shall include costs paid to distributors.

1.30   "Morbidity Associated  SNP(s)":  shall mean those Project SNPs for which
        ------------------------------
       [...***...] has been detected.

2      RESEARCH PROJECT

2.1    Project Scope.  The objectives and the scope of the Project are to
       -------------
conduct scientific research for the generation of Project Results using
MassArray and Pooling Technologies

                                      5.    *** Confidential Treatment Requested
<PAGE>

     and Project SNPs for the purpose of generating Assays and Collaboration IP.
     The Project is described in greater detail in Exhibit A.

2.2  Project Deliverables.
     --------------------

     (a)  Beginning on the Effective Date, Incyte will transfer to Sequenom
          [...***...], and Sequenom will generate Assays and Project Results.
          Incyte will transfer to Sequenom additional SNPs [...***...],
          sufficient to enable the generation of a total of one hundred thousand
          (100,000) Assays for Project SNPs, and Sequenom will generate Project
          Results with respect to each of those Project SNPs.
     (b)  Sequenom shall promptly deliver to Incyte all Project Results.
     (c)  Incyte and Sequenom shall have the option to conduct follow-up work
          involving Disease Association Data upon mutual written agreement.

2.3  Consents.  Sequenom will obtain all consents, releases, permits and other
     ---------
     authorization required by all applicable federal, state, local and foreign
     governmental authorities and agencies thereof for the collection and use of
     samples from patients and human volunteers necessary to allow Sequenom to
     generate the Project Results and to allow the Project Results to be
     utilized for all purposes contemplated under this Agreement.

2.4  Principal Contacts.  Incyte and Sequenom will each designate an employee
     ------------------
     who will act as the primary contact person who shall be responsible for
     coordinating the Parties' collaboration on the Project and the generation
     of Project Results. Incyte's initial contact person will be [...***...],
     and Sequenom's initial contact person will be [...***...]. Each Party will
     have the right to designate a substitute primary contact person by written
     notice to the other Party.

2.5  Additional Project SNPs.  Sequenom and Incyte shall mutually determine
     which Project SNPs are [...***...]. After Sequenom and Incyte have so
     determined, then Incyte will deliver to Sequenom the [...***...], as Incyte
     determines according to its standard procedures, for further work under the
     Project. In addition, if either Party uses the [...***...] to determine
     [...***...], then [...***...] shall thereafter be included within the
     definition Project SNPs as defined hereunder.

3    BACKGROUND TECHNOLOGY ACCESS AND LICENSES

3.1  Sequenom License Under Incyte Technology.  Subject to the terms and
     -----------------------------------------
     conditions of this Agreement, Incyte hereby grants Sequenom (a) [...***...]
     license under the Incyte Technology to perform Sequenom's obligations in
     connection with the Project, and (b) [...***...] license under the Incyte
     Technology [...***...]. Sequenom acknowledges that the foregoing license
     [...***...].

                                      6.    *** Confidential Treatment Requested
<PAGE>

     [...***...]. Incyte will provide Sequenom with [...***...] that Sequenom
     may provide to any End User [...***...] so that, if it wishes to do so,
     such End User may obtain the right to use isSNP Sequence Data for such SNP.
     So long as isSNP Sequence Data is offered by Incyte commercially, Incyte
     will make reasonable efforts to make available to End User(s), if such End
     User so requests, the right to obtain isSNP Sequence Data from Incyte on
     then available terms and conditions. [...***...].

3.2  Incyte Right to Purchase Assays.  Subject to the terms and conditions of
     -------------------------------
     this Agreement, Sequenom agrees to sell to Incyte, and Incyte will have the
     right to purchase from Sequenom, Assays for Incyte's use in connection with
     [...***...]. Sequenom shall make available for purchase by Incyte the type
     of Assays which are available for Sequenom or any third party and in
     quantities similar to those made available to Sequenom or any third party.
     Sequenom will sell Assays to Incyte on terms and conditions [...***...].

3.3  Sequenom Access to Project SNPs.  Sequenom may use the Project SNPs in
     -------------------------------
     conjunction with Pooling Technology [...***...] for the purposes of
     [...***...]. Sequenom will not use the Project SNPs in conjunction with
     Pooling Technology in connection with [...***...]. Subject to the terms and
     conditions of this Agreement, Incyte agrees to sell to Sequenom, and
     Sequenom will have the right to purchase from Incyte, Incyte information
     products which contain Project SNPs for Sequenom's use as an End User of
     Assays. Incyte will sell such Incyte information products containing
     Project SNPs to Sequenom on terms and conditions [...***...] For use in
     Partnership Programs, Incyte shall make information products containing
     Project SNPs available to the Partnership Program [...***...]

3.4  Incyte Access to Pooling Technology.  Incyte may use the Pooling Technology
     ------------------------------------
     through Sequenom [...***...] for the purposes of [...***...]. Incyte will
     not use the Pooling Technology in connection with the provision of
     [...***...].

                                      7.    *** Confidential Treatment Requested
<PAGE>

3.5  No Implied Licenses.  No implied right or license is granted by either
     -------------------
     Party to the other to utilize any intellectual property in a manner not
     expressly included within the scope of the licenses granted pursuant to
     this Agreement.  Other than as expressly granted herein, no licenses either
     by estoppel, implication or otherwise are granted herein.

4    RIGHTS IN PROJECT RESULTS

4.1  Incyte Rights.  Incyte shall have (a) subject to the provisions of Section
     -------------
     6.7, the [...***...] right to [...***...], and (b) subject to the
     provisions of Section 6.7, the [...***...] right to [...***...], and (c)
     subject to the provisions of Sections 6.6, the [...***...] right to
     [...***...], and (d) subject to the provisions of Section 6.10, the
     [...***...] right to [...***...], and (e) the [...***...] right to
     [...***...] subject to the provisions of Section 5.1. If [...***...] during
     [...***...] Incyte does not have [...***...].

4.2  Sequenom Rights.  Sequenom shall have, subject to the payments to Incyte
     ---------------
     under Section 6.3, the exclusive right to use the Project Results to
     develop, manufacture and sell Assays for mass spectrometry-based
     applications for use by End Users. Sequenom will use commercially
     reasonable efforts to develop and commercialize Assays, consistent with the
     exercise of prudent scientific and business judgment as applied to other
     products of similar potential and market size. If [...***...] during
     [...***...] Sequenom has not [...***...].

4.3  Partnership Programs.  Except as expressly provided in this Agreement,
     --------------------
     neither party can distribute or disclose [...***...] without the prior
     written consent of the other Party.

     (a)  In the event that a Party (the "Proposing Party") wishes to use the
          Project Results in a Partnership Program, the Proposing Party will
          provide written notice to the other Party (the "Other Party")
          [...***...] and [...***...]. The Other Party will have [...***...]
          from the date of written notice from the Proposing Party to elect

                                      8.    *** Confidential Treatment Requested
<PAGE>

          whether to participate in the Partnership Program by providing written
          notice to the Proposing Party.  The Other Party may reject any
          Partnership Program if [...***...] determines that [...***...] are
          [...***...] or if [...***...].  If the Other Party rejects such
          Partnership Program [...***...], the Proposing Party [...***...].

     (b)  If the Other Party elects to participate in the Partnership Program,
          Incyte will provide access to the Project SNPs, Sequenom will provide
          access to the Pooling Technology and the Mass Array Technology and the
          Parties will provide access to those Project Results determined to be
          relevant to the Partnership Program to the Collaborator for the
          purposes of the Partnership Program.
     (c)  If the Other Party elects not to participate in the Partnership
          Program, the Proposing Party may [...***...], and the Other Party will
          [...***...].

5    COLLABORATION IP

5.1  Joint Ownership.  Incyte and Sequenom will jointly own the Collaboration
     ---------------
     IP, subject to the limitations on use set forth in this Agreement. Incyte
     will have primary responsibility for filing and prosecuting patent
     applications or other rights included in the Collaboration IP. Incyte will
     provide Sequenom the opportunity to review and comment on all such matters
     in advance of any filings made or other actions taken by or on behalf of
     Incyte, will take into account and act upon all reasonable suggestions made
     by Sequenom and will promptly provide Sequenom with copies of all
     correspondence sent or received by Incyte with respect to the Collaboration
     IP from governmental patent agencies or other authorities. Sequenom shall
     execute such documents and instruments, take such steps, and provide such
     assistance, as Incyte may reasonably request in connection with such
     activities. If Incyte determines not to file or pursue prosecution of, or
     to abandon, patent applications or other rights included in the
     Collaboration IP, Sequenom shall have the right, at its option, to
     undertake such activities, and Incyte shall execute such documents and
     instruments, take such steps, and provide such assistance, as Sequenom may
     reasonably request in connection with such activities. Each Party will
     reimburse the other Party (the "Filing Party") [...***...] of all out-of-
     pocket costs incurred by the Filing Party in connection with the filing and
     prosecution of all such patents and patent applications and other rights
     for which it is responsible under this Section 5.1.

5.2  Enforcement.  If either Party becomes aware of any infringement of any
     -----------
     Collaboration IP by any third party, it shall promptly notify the other
     Party. The Parties shall use reasonable efforts to agree on a strategy for
     enforcement of any such Collaboration IP

                                      9.    *** Confidential Treatment Requested
<PAGE>

     against any such third party.  If the Parties agree on a strategy, all
     enforcement shall be undertaken in the names of both Parties and using
     counsel approved by both Parties, and the Parties shall share the costs of
     enforcement equally and shall divide equally all damages recovered in
     connection with such enforcement efforts and all amounts paid in settlement
     of any such enforcement efforts.  If one of the Parties wishes to enforce
     any Collaboration IP, and the other Party does not wish to do so, then the
     Party wishing to enforce the Collaboration IP shall have the right to do
     so, at its own expense, and shall have the right to retain any damages
     recovered in connection with such enforcement efforts, and all amounts paid
     in settlement of any such enforcement efforts.

5.3  Collaboration IP.  Neither Party may use, grant any license under, transfer
     ----------------
     or disclose Collaboration IP to any third party, [...***...] without the
     [...***...].

6    FEES AND REVENUE SHARING

6.1  Sequenom Fee for isSNP Dataset and License Under Incyte Technology.  Upon
     ------------------------------------------------------------------
     the Effective Date, Sequenom shall pay to Incyte [...***...] as a one-time,
     nonrefundable fee for Incyte's grant to Sequenom of the rights granted
     under Section 3.1 for the Project and for access to the isSNP Dataset in
     accordance with this Agreement.

6.2  Incyte Fee for Access to MassArray and Pooling Technology.  Upon the
     ---------------------------------------------------------
     Effective Date, Incyte will pay to Sequenom [...***...] as a one-time,
     nonrefundable technology access fee to MassArray Technology for the
     Project.

6.3  Assays.  Sequenom shall pay to Incyte [...***...] of Sequenom's Revenue on
     ------
     the sale of Assays pursuant to the license granted by Incyte under Section
     3.1 or using any Collaboration IP.

6.4  Partnership Programs.  If, pursuant to Section 4.3, the Parties enter into
     --------------------
     any Partnership Program with a Collaborator, the Parties will [...***...]
     any Contribution Margin with respect to products and services included in
     the Partnership Program.

6.5  Collaboration IP Licensing.  Incyte shall have the sole responsibility for
     --------------------------
     licensing Collaboration IP. If a Incyte grants to any third party a license
     under any Collaboration IP, then Incyte will pay to Sequenom [...***...] of
     the Contribution Margin from the grant of such license.

6.6  Morbidity Data.  (a) If Incyte includes the Morbidity Data in an Incyte
     --------------
     information product that consists [...***...], Incyte shall pay to Sequenom
     [...***...] of Incyte's Revenue on the sale or license of such information
     product,

                                      10.   *** Confidential Treatment Requested
<PAGE>

     provided however, that [...***...] an information product which contains
     [...***...].  (b) Incyte and Sequenom will negotiate in good faith as to
     whether Incyte may include [...***...] and, if so, [...***...].

6.7  Confirmation and Frequency Data.  (a) If Incyte includes some or all of the
     --------------------------------
     isSNP Dataset and Confirmation Data and/or Frequency Data in the Incyte
     Databases or any other Incyte information product that includes information
     other than the isSNP Dataset and the Project Results [...***...], then
     Incyte [...***...]. (b) If, [...***...], Incyte provides some or all of the
     isSNP Dataset and Frequency Data [...***...], Incyte shall [...***...].

6.8  Payment.  Payments made pursuant to Section 6.1 and 6.2 shall be paid
     -------
     within thirty (30) days of the Effective Date. Within forty-five (45) days
     after the end of each calendar quarter, each Party will submit a written
     statement, certified to be accurate by an authorized employee of the Party
     providing the statement, setting forth the amounts payable by that Party to
     the other pursuant to Sections 6.3 through 6.7, as applicable. The
     statement shall provide sufficient detail to enable the receiving Party to
     calculate the amount owed by the Party submitting the statement. Each such
     statement shall be accompanied by payment of the amount, if any, owed by
     the Party who prepared the statement.

6.9  Records.  Each Party shall keep for three (3) years from the date of any
     -------
     payment hereunder complete and accurate records sufficient to enable the
     other Party to verify the accuracy of the payments made hereunder
     (including, without limitation, with respect to Sequenom, records regarding
     sales of Assays pursuant to Section 6.3 and, with respect to Incyte,
     records regarding sales of Incyte information products pursuant to Sections
     6.6 (a) and 6.7 (b) and licenses under Section 6.5 and to support any
     adjustment to the percentage of Revenue payable under Section 6.3, 6.6 (a)
     or 6.7 (b). Upon reasonable notice to the other Party, either Party will
     have the right to have an independent certified public accountant
     reasonably acceptable to the other Party (and which has signed a
     confidentiality agreement with regard to audited Party's Confidential
     Information but which allows disclosure of the results of such inspection
     to the auditing Party) inspect the relevant records during regular business
     hours at such place or places where such records are customarily kept. Such
     inspection right shall not be exercised more than once in any calendar
     year. The Party causing such inspection shall bear the full cost of such
     inspection unless such inspection discloses a variance of more than five
     percent (5%) from the amount of the payments due under this Agreement. In
     such case, the audited Party shall bear the full cost of such inspection
     and shall promptly remit to the other Party the amount of any underpayment,
     together with interest from the date originally due. In

                                             ***Confidential Treatment Requested

                                      11.
<PAGE>

      accordance with the provisions of Article 7, each Party agrees to hold in
      strict confidence all information concerning such records and reports as
      well as any information learned in the course of any audit or inspection
      of the other Party's records. The foregoing notwithstanding, each Party
      maintains the right to reveal such information to the extent necessary in
      order to enforce its rights under this Agreement. The failure of a Party
      to request verification of any report or statement during said three-year
      period shall be considered acceptance of the accuracy of such report. The
      results of each inspection, if any, shall be binding on both Parties.

6.10  Incyte Patent Rights Licensing - Frequency Data.  Incyte shall pay to
      -----------------------------------------------
      Sequenom [...***...] of Revenues from third parties by Incyte with respect
      to any product or method performed, the development or commercialization
      of which, but for the specific license granted by Incyte to that third
      party infringe a valid claim of a patent which in the specification
      contains Frequency Data. [...***...]. Notwithstanding the foregoing, in no
      case shall Incyte's payment to any third party under any Incyte patent in
      Incyte Patent Rights be greater than [...***...] of such Revenue to which
      this Section 6.10 applies. If Incyte reduces the percentage of such
      Revenue payable to Sequenom, then it shall reduce the percentage of such
      Revenue payable to third parties pro rata.

6.11  Adjustments.  The percentage of Revenue specified in Sections 6.3, 6.5,
      ------------
      6.6 and 6.7 is intended to represent [...***...] of a Party's Contribution
      Margin on applicable products and services. Up to once in any contract
      year, either Party may request a review of the percentage of Revenue
      payable under Paragraphs 6.3 through 6.7. If based upon such review, that
      the percentage of Revenue payable should be adjusted to represent
      [...***...] of Contribution Margin based on the paying Party's actual Cost
      of Goods Sold and Sales and Marketing Expenses, then the paying Party will
      so adjust such percentage and pay according to such percentage from that
      point forward. In any case, the percentage of Revenue payable by one Party
      to the other pursuant to Paragraphs 6.3 through 6.7, shall not be less
      than [...***...]

7     CONFIDENTIALITY AND PUBLICATION

7.1   Confidentiality.  During the term of this Agreement and for five (5) years
      ---------------
      thereafter, each Party shall keep confidential, shall not publish or
      otherwise disclose, and shall not use for any purpose (except those
      expressly permitted under this Agreement), any Confidential Information of
      the other Party pursuant to this Agreement. Such confidentiality
      obligations of Sequenom with respect to isSNP Sequence Data which is
      Incyte Confidential Information shall be perpetual. Neither Party can
      distribute or disclose Morbidity Data and Collaboration IP, whether in
      connection with a proposed Partnership Program or Outside Program or
      otherwise, without the prior written consent of the other Party.

7.2   Permitted Disclosures.  Each Party may disclose the other Party's
      ---------------------
      Confidential Information to the extent such disclosure is reasonably
      necessary in:

                                             ***Confidential Treatment Requested

                                      12.
<PAGE>

     (a)  filing, prosecuting and maintaining patent applications and patents as
          provided for under Article 5;

     (b)  prosecuting or defending litigation related to this Agreement or the
          subject matter thereof; or

     (c)  complying with applicable laws, governmental regulations (including
          those relating to product development and regulatory approval) or
          court orders; provided, however, if a Party is required to make any
          such disclosure of the other Party's Confidential Information under
          this Section 7.2, the disclosing Party will give reasonable advance
          notice to the other Party of such disclosure requirement and will use
          reasonable efforts to secure confidential treatment of such
          Confidential Information as is required to be disclosed;

     (d)  connection with Incyte distribution of Incyte's information products
          that include some or all of the Project Results in accordance with the
          terms of this Agreement as long as Incyte first notifies Sequenom of
          any Sequenom Confidential Information that Incyte reasonably believes
          is necessary for disclosure for such distribution purpose, and
          Sequenom consents, such consent not to be unreasonably withheld by
          Sequenom, provided however that such notice and consent requirement
          will not apply to the disclosure of Project Results or Collaboration
          IP) or

     (e)  Sequenom 's contract services with third parties to manufacture
          primers provided that (i) such services are solely for the benefit of
          Sequenom, (ii) no intellectual property rights are transferred to such
          third party provider, and (iii) any transfer of isSNP Sequence Data
          shall be subject to obligations of confidentiality non-disclosure and
          non-use which are no less stringent than those in this Agreement
          without any further permitted disclosure.

7.3  Publications.  Sequenom and Incyte shall have the right, within the
     ------------
     licenses granted under this Agreement, to publish or publicly present
     (orally or in writing) Project Results at professional conferences or other
     scientific meetings or publications upon their mutual written agreement.

8    TERM AND TERMINATION

8.1  Term and Termination.  This Agreement shall commence as of the Effective
     --------------------
     Date and shall continue [...***...].

8.2  Termination for Material Breach.  Either Party shall have the right to
     -------------------------------
     terminate this Agreement, at any time by written notice to the breaching
     Party, upon material breach of any obligation under this Agreement and
     failure of the breaching Party to cure the breach within thirty (30) days
     of its receipt of written notice of breach.

8.3  Termination for Project Failure.  Each Party shall have the right to
     --------------------------------
     terminate this Agreement for the following reasons:
     (a)  either Party may terminate this Agreement upon written notice to the
          other Party if [...***...] based upon

                                             ***Confidential Treatment Requested

                                      13.
<PAGE>

     [...***...] is [...***...] or
     (b)  Incyte may terminate this Agreement upon written notice to Sequenom if
          [...***...]

8.4  Effects of Termination.
     ----------------------

     (a)  Upon termination of this Agreement by either Party pursuant to Section
          8.3(a):  (i) [...***...]; and (ii)  [...***...] and (iii) [...***...].

     (b)  Upon termination of this Agreement by Sequenom pursuant to Section
          8.2: (i) [...***...]; (ii) [...***...]; and (iii) [...***...].

     (c)  Upon termination of this Agreement by Incyte pursuant to Section 8.2:
          (i) [...***...]; (ii) [...***...]; and (iii) [...***...].

     (d)  Upon termination of this Agreement by Incyte pursuant to Section
          8.3(b): (i) [...***...]; (ii) [...***...]; and (iii) [...***...].

                                            *** Confidential Treatment Requested

                                      14.
<PAGE>

     [...***...].

8.5  Survival.  Expiration or termination of this Agreement shall not relieve
     --------
     the Parties of any obligation accruing prior to such expiration or
     termination. The obligations and rights of the Parties under [...***...]
     shall survive expiration or termination of this Agreement.

8.6  Return of Confidential Information.  Within thirty (30) days following the
     ----------------------------------
     expiration or termination of this Agreement, except to the extent and for
     so long as a Party retains rights under Section 8.4 (and the provisions
     referred to therein), each Party shall deliver to the other Party any and
     all Confidential Information of the other Party in its possession.

9    REPRESENTATIONS AND WARRANTIES

9.1  Representations and Warranties.  Each Party represents and warrants to the
     ------------------------------
     other Party that:

     (a)  it has the power, authority and the legal right to enter into this
          Agreement;

     (b)  it is not under any obligation to any person or entity, contractual or
          otherwise, that would conflict with the terms of this Agreement;

     (c)  the execution and delivery of this Agreement and the performance of
          the transactions contemplated hereby have been duly authorized by all
          necessary action of such Party;

     (d)  the execution and delivery of this Agreement and the performance by
          such Party of any of its obligations under this Agreement do not (i)
          conflict with, or constitute a breach or violation of, any other
          contractual obligation to which it is a party, any judgment of any
          court or governmental body applicable to such Party or its properties
          or, to such Party's knowledge, any statute, decree, order, rule or
          regulation of any court or governmental agency or body applicable to
          such Party or its properties, and (ii) with respect to the execution
          and delivery of this Agreement, require any consent or approval of any
          governmental authority or other person; and

     (e)  this Agreement is a legal, valid and binding obligation of it
          enforceable against it in accordance with its terms and conditions,
          except as such enforceability may be limited by applicable bankruptcy,
          insolvency, moratorium, reorganization or similar laws, from time to
          time in effect, affecting creditor's rights generally.

9.2  Disclaimers and Limitations.
     ---------------------------

     (a)  NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE
          OR WARRANTY GIVEN BY EITHER PARTY TO THE OTHER THAT ANY PATENT WILL
          ISSUE BASED UPON ANY

                                             ***Confidential Treatment Requested

                                      15.
<PAGE>

          PENDING PATENT APPLICATION WITHIN THE INCYTE PATENT RIGHTS OR
          COLLABORATION IP, THAT ANY PATENT WITHIN THE INCYTE PATENT RIGHTS OR
          COLLABORATION IP THAT HAS ISSUED OR ISSUES WILL BE VALID, OR THAT THE
          USE OF ANY LICENSE GRANTED HEREUNDER OR THE USE OF ANY INCYTE PATENT
          RIGHTS OR COLLABORATION IP WILL NOT INFRINGE THE PATENT OR PROPRIETARY
          RIGHTS OF ANY OTHER PERSON.  NEITHER PARTY MAKES ANY REPRESENTATIONS
          OR WARRANTIES WITH RESPECT TO THE OTHER PARTY'S USE OF INFORMATION OR
          RIGHTS HEREUNDER.  ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING
          WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE OR
          NONINFRINGEMENT, ARE DISCLAIMED.

     (b)  INCYTE MAKES NO WARRANTY THAT THE ISSNP DATASET DOES NOT CONTAIN
          ERRORS.

     (c)  EXCEPT AS EXPLICITLY STATED HEREIN NEITHER PARTY WILL BE LIABLE FOR
          CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES OF ANY NATURE ARISING
          FROM OR RELATING TO THIS AGREEMENT; PROVIDED, HOWEVER, THAT THIS
          LIMITATION SHALL NOT LIMIT THE INDEMNIFICATION OBLIGATION OF SUCH
          PARTY UNDER SECTION 10.1 BELOW FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES
          RECOVERED BY A THIRD PARTY.

10   INDEMNITY

10.1 Indemnification Obligation.  Each Party shall indemnify and hold the other
     --------------------------
     Party and its Affiliates, officers, directors, employees, consultants and
     agents harmless from and against any losses, liabilities, damages and
     expenses (including reasonable attorney's fees and costs) incurred as a
     result of any third party claim, demand, action or other proceeding to the
     extent resulting from a breach of the indemnifying Party's warranties or
     out of the recklessness or intentional misconduct of the indemnifying Party
     or its affiliates in connection with activities under this Agreement except
     to the extent such losses, liabilities, damages and expenses (including
     reasonable attorney's fees and costs) resulted from the recklessness or
     intentional misconduct of the other Party.

10.2 Breach of Confidentiality.  Each Party acknowledges and agrees that with
     -------------------------
     respect to the nature of Confidential Information of the other Party, there
     can be no adequate remedy at law for any breach of the obligations under
     the confidentiality provisions of this Agreement and that any such breach
     may result in irreparable harm to the other Party. Therefore, upon any such
     breach, such other Party shall be entitled to appropriate equitable relief
     in addition to whatever remedies it might have at law, including injunctive
     relief, specific performance or such other relief as such other Party may
     request to enjoin or otherwise restrain any act prohibited hereby, as well
     as the recovery of all costs and expenses, including reasonably attorney's
     fees incurred. Each Party shall be entitled to indemnification by the other
     Party from any losses, liabilities, damages and expenses (including
     reasonable attorney's fees and costs) incurred by such Party as a result of
     or in connection with such breach.

                                      16.
<PAGE>

11   MISCELLANEOUS

11.1 Notices. All notices shall be in writing and addressed as follows, or to
     -------
     such other address as may be designated from time to time. All notices
     shall be effective upon receipt.

     If to SEQUENOM with respect to all technical and non-technical matters:

               Sequenom, Inc.
               11555 Sorrento Valley Road
               San Diego, CA 92121
               Attention: Chief Executive Officer

     If to Incyte with respect to all non-technical matters:

               Incyte Genomics, Inc.,
               3174 Porter Drive,
               Palo Alto, CA 94304
               Attention: Chief Executive Officer

               If to Incyte with respect to all technical matters:

               Incyte Genomics, Inc.,
               3174 Porter Drive,
               Palo Alto, CA 94304
               Attention: [...***...]

11.2 Governing Law.  This Agreement shall be governed by and construed in
     -------------
     accordance with the laws of the State of California, without regard to the
     conflicts of law principles thereof.

11.3 Entire Agreement of the Parties and Amendments.  This Agreement (including
     ----------------------------------------------
     Exhibit A attached hereto) represents the entire understanding and
     agreement of the Parties and supersedes any and all prior representations,
     understandings and agreements, whether oral or written, with respect to the
     subject matter hereof. No waiver, modification or amendment of any
     provision of this Agreement shall be valid or effective unless made in
     writing and signed by a duly authorized officer of each of the Parties.

11.4 Counterparts. This Agreement may be executed by the Parties in two or more
     ------------
     counterparts and each counterpart shall be deemed an original.

11.5 No Waiver.  The delay or failure of either Party at any time or times to
     ---------
     require performance of any provisions shall not affect the rights at a
     later time to enforce the same. No waiver by either Party of any condition
     or of the breach of any term contained in this Agreement, whether by
     conduct, or otherwise, in any one or more instances, shall be deemed to be,
     or considered as, a further or continuing waiver of any such condition or
     of the breach of such term or any other term of this Agreement.

                                             ***Confidential Treatment Requested

                                      17.
<PAGE>

11.6   Assignment of this Agreement.  Neither this Agreement nor any right or
       ----------------------------
       interest herein may be assigned in whole or in part by either Party
       (whether voluntarily, by operation of law or otherwise) without the prior
       written consent of the other Party; provided, however, that either Party
       may assign this Agreement and the rights and interest therein, in whole
       or in part, without the other Party's consent, (a) to any of its
       Affiliates, or (b) to any third party purchaser of all or substantially
       all of its assets to which this Agreement pertains, or in connection with
       the merger, consolidation, change in control or similar transaction
       involving the assigning Party. In the event of any such transaction
       described in clause (b), intellectual property rights of such third party
       purchaser will not be included in any technology licensed hereunder. Any
       assignment not in accordance with the above shall be void.

11.7   Force Majeure.  Neither Sequenom nor Incyte shall be liable for failure
       -------------
       of or delay in performing obligations set forth in this Agreement, and
       neither shall be deemed in breach of its obligations, if such failure or
       delay (other than a failure or delay with respect to any payment) is due
       to natural disasters or any causes reasonably beyond the control of
       Sequenom or Incyte.

11.8   No Trademark Rights.  Except as otherwise provided herein, no right,
       -------------------
       express or implied, is granted by this Agreement to use in any manner the
       names of "Incyte" or "Sequenom," or any other trade name or trademark of
       Incyte or Sequenom in connection with the performance of this Agreement
       or in any advertisement.

11.9   Public Announcements.  The Parties will mutually agree on a public
       --------------------
       announcement of the Project following execution of this Agreement.
       Neither Party will have the right to publicly disclose the existence or
       terms of this Agreement without the consent of the other party, except
       insofar as necessary for either Party to comply with any applicable laws
       or government regulations.

11.10  No Third Party Beneficiaries.  No third party, including any employee of
       ----------------------------
       any Party, shall have or acquire any rights by reason of this Agreement.
       Nothing construed in this Agreement shall be deemed to constitute the
       Parties partners with each other or any third party.

11.11  Other Activities.  Notwithstanding the provisions of this Agreement, each
       ----------------
       Party retains the right to undertake research and development programs or
       to establish collaborations with third parties in any area, including
       areas which are or become the subject of this Agreement, consistent with
       the licenses, options and other rights expressly granted to the other
       Party under this Agreement.

11.12  Compliance with Law.  Each Party shall comply with all applicable laws,
       -------------------
       rules, regulations and guidelines in connection with that Party's
       performance of its obligations under this Agreement.

                                      18.
<PAGE>

11.13  Disputes.  For any disputes arising under this Agreement, the Parties
       --------
       shall first use all reasonable efforts, including direct discussion and
       mediation, to amicably resolve the disputes. If, after ninety (90) days,
       the Parties fail to resolve the dispute, either Party may submit the
       dispute to final and binding arbitration under the Commercial Arbitration
       Rules of the American Arbitration Association in San Francisco,
       California U.S.A. Such arbitration shall be conducted by a panel of three
       (3) arbitrators appointed in accordance with those rules. The costs of
       the arbitration, including administrative and arbitrators' fees, shall be
       shared equally by the Parties. Each Party shall bear its own costs
       (including attorneys' fees). However, the prevailing Party, as determined
       by the arbitration panel, shall be entitled to an award against the other
       Party, in the amount of the prevailing Party's costs, reasonable
       attorneys' fees and any arbitration administration fees. Neither Party
       may disclose the existence, content or results of any arbitration
       hereunder without the prior written consent of both Parties.

11.14  Prevailing Agreement.  In the event of any inconsistency between this
       --------------------
       Agreement and the Project attached as Exhibit A, this Agreement shall
       prevail.

       IN WITNESS WHEREOF, the Parties have executed this Agreement on the dates
set forth below:

Sequenom, Inc.                          Incyte Genomics, Inc.

By: /s/ Toni Schuh                      By: /s/ Lee Bendekgey
    -----------------------               ----------------------------

Name: Toni Schuh                        Name: Lee Bendekgey
      ---------------------                   ------------------------

Title: President, CEO                   Title: EVP, General Counsel
       --------------------                    -----------------------

                                      19.
<PAGE>

                                   Exhibit A

                                   Exhibit A
                        INCYTE / SEQUENOM SCIENCE PLAN

[...***...]

                                             ***Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}]]